Cel-Sci Corp. (CVM; 871006) - 500 Beiträge pro Seite (Seite 16)
eröffnet am 30.10.03 18:31:27 von
neuester Beitrag 11.02.15 00:07:02 von
neuester Beitrag 11.02.15 00:07:02 von
Beiträge: 7.656
ID: 791.230
ID: 791.230
Aufrufe heute: 0
Gesamt: 442.330
Gesamt: 442.330
Aktive User: 0
Top-Diskussionen
Titel | letzter Beitrag | Aufrufe |
---|---|---|
vor 44 Minuten | 2932 | |
vor 10 Minuten | 2255 | |
vor 11 Minuten | 2023 | |
vor 1 Stunde | 1815 | |
vor 3 Minuten | 1531 | |
vor 1 Stunde | 1373 | |
heute 11:04 | 1228 | |
vor 46 Minuten | 1127 |
Meistdiskutierte Wertpapiere
Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
---|---|---|---|---|---|---|---|
1. | 1. | 18.500,48 | -0,12 | 98 | |||
2. | 9. | 0,2105 | -3,22 | 65 | |||
3. | 17. | 2,6200 | -14,94 | 65 | |||
4. | 4. | 2.231,78 | +1,79 | 55 | |||
5. | 2. | 0,1795 | -84,04 | 52 | |||
6. | 7. | 0,9470 | +13,55 | 28 | |||
7. | 5. | 162,70 | -1,88 | 28 | |||
8. | 19. | 0,1030 | -3,74 | 24 |
hätte ich doch besser ausgepasst vor 40 Jahren in der Schule, wer kann das mal verständlich übersetzen in kurzen Worten ?
http://www.sec.gov/Archives/edgar/data/725363/00010048781300…
http://www.sec.gov/Archives/edgar/data/725363/00010048781300…
ich könnt kotzen
Antwort auf Beitrag Nr.: 44.939.655 von ALF-FRED am 27.06.13 20:55:16kommen 20 Mio. neue Aktien dazu...bin derzeit nicht drin, aber auf Watch........denk so bei 0,20 US$ wäre erst mal ein guter Start wieder...werds mal versuchen...4 Positionen 0,18 -0.22 US$...mal setzen
Antwort auf Beitrag Nr.: 44.940.369 von Expertchen007 am 27.06.13 22:14:10und 800 Mio. sind möglich gesamt...so wie ich das lese
********************
3) subject to the determination of CEL-SCI's directors that an increase in
CEL-SCI's authorized capital would be in the best interest of CEL-SCI's
shareholders, the adoption of an amendment to CEL-SCI's Articles of
Incorporation such that CEL-SCI would be authorized to issue up to 800,000,000
shares of common stock. The Board of Directors may elect not to proceed with
increasing CEL-SCI's authorized capital without further action by the
shareholders; and
(4) the appointment of BDO USA, LLP as CEL-SCI's independent registered
public accounting firm for the fiscal year ending September 30, 2013;
The following is a tabulation of votes cast with respect to these
proposals:
Votes
-------------------------------------- Broker
Proposal For Against Abstain Non-Votes
1. 208,502,239 27,744,607 13,469,847
2. 156,067,768 89,649,626 3,999,299
3. 190,425,399 48,391,841 10,899,453
4. 236,020,249 5,940,917 7,755,527
The adoption of CEL-SCI's 2013 Non-Qualified Stock Option Plan, which
provides that up to 20,000,000 shares of common stock may be issued upon the
exercise of options granted pursuant to the Non-Qualified Plan, did not receive
the required number of votes.
********************
3) subject to the determination of CEL-SCI's directors that an increase in
CEL-SCI's authorized capital would be in the best interest of CEL-SCI's
shareholders, the adoption of an amendment to CEL-SCI's Articles of
Incorporation such that CEL-SCI would be authorized to issue up to 800,000,000
shares of common stock. The Board of Directors may elect not to proceed with
increasing CEL-SCI's authorized capital without further action by the
shareholders; and
(4) the appointment of BDO USA, LLP as CEL-SCI's independent registered
public accounting firm for the fiscal year ending September 30, 2013;
The following is a tabulation of votes cast with respect to these
proposals:
Votes
-------------------------------------- Broker
Proposal For Against Abstain Non-Votes
1. 208,502,239 27,744,607 13,469,847
2. 156,067,768 89,649,626 3,999,299
3. 190,425,399 48,391,841 10,899,453
4. 236,020,249 5,940,917 7,755,527
The adoption of CEL-SCI's 2013 Non-Qualified Stock Option Plan, which
provides that up to 20,000,000 shares of common stock may be issued upon the
exercise of options granted pursuant to the Non-Qualified Plan, did not receive
the required number of votes.
Reserve Split siehe Commerzbank,eher wohl bei den meisten ein Trauerspiel
Zitat von vfbler74: Reserve Split siehe Commerzbank,eher wohl bei den meisten ein Trauerspiel
Denke, Du meinst Reverse-Split - Verringerung der Aktienanzahl.
Unter einem Reverse Split wird die Zusammenfassung mehrerer Aktien zu einem Papier verstanden. Der Anleger hat beispielsweise nicht mehr 100 Aktien, sondern nach einem Reverse Split von 5 zu 1 nur noch 20 Aktien
Das ist nicht das Thema, sondern Ausgabe von neuen Aktien, also eine Erhöhung.
Obwohl ich einen späteren Reverse-Split nicht ausschliesse, um den Kurs ( nach solch einer Verwässerung) wieder attraktiver erscheinen zu lassen
Gefahr des Delistings an der NYSE MKT
http://www.sec.gov/Archives/edgar/data/725363/00010048781300…
Cel-Sci hat bis zum 19.August Zeit, einen akzeptabelen Plan einzureichen.
Ich denke, das kriegen die hin.
http://www.sec.gov/Archives/edgar/data/725363/00010048781300…
Cel-Sci hat bis zum 19.August Zeit, einen akzeptabelen Plan einzureichen.
Ich denke, das kriegen die hin.
ist die firma schon tot?null beiträge hier?was wird in usa über cel sci geschrieben?
Antwort auf Beitrag Nr.: 45.083.011 von vfbler74 am 20.07.13 09:54:39bei yahoo nur Müll, ich lese da schon gar nicht mehr,
bei dem Kurs sehe ich wohl auch ein Split kommen,
mehr als abwarten auf Studienergebnisse kann man auch nicht,
ich warte schon über 10 Jahre jetzt, ist echt Kacke der Verlauf,
egal was kommt, ich hoffe in 3 - 4 Jahren bin ich raus aus der Aktie, so oder so z.Z. über 60% Miese
bei dem Kurs sehe ich wohl auch ein Split kommen,
mehr als abwarten auf Studienergebnisse kann man auch nicht,
ich warte schon über 10 Jahre jetzt, ist echt Kacke der Verlauf,
egal was kommt, ich hoffe in 3 - 4 Jahren bin ich raus aus der Aktie, so oder so z.Z. über 60% Miese
oder totalverlust.....hatte mal Westhawk,öl und gasbranche....die versuchten wenigstens immer den kurs mit guten meldungen zu pushen,ging aber auch schief...versuchte nun seit jahren hier mein glück und hoffte daß das ding mal auf 5 oder 6 dollar steigt,leider fehlanzeige....nach einem splitt( was soll das für ein vorteil sein? )müßte die aktie ja dann auf 50 oder 60 dollar!wieso hier nicht gepusht wird,versteh ich nicht. eine kapitalerhöhung mach ich doch lieber bei einem hohen kurs,ist doch viel weniger verwässerung da,oder bin ich blöd? statt bei 0,20 cent und muß viel aktien ausgeben.das ist doch der nachteil für die altaktionäre,was aber immer von ihnen anders verkauft wird?
Antwort auf Beitrag Nr.: 45.085.625 von vfbler74 am 21.07.13 10:06:42Moin,
grausam wie es sich entwickelt,
aber jemand hat gestern für 1000 Euro gekauft,
war bestimmt expertchen der Zocker,
von cel. kommt aber auch nix zum gegensteuern,
auf einen sonnigen heißen Tag
Alf-Fred
grausam wie es sich entwickelt,
aber jemand hat gestern für 1000 Euro gekauft,
war bestimmt expertchen der Zocker,
von cel. kommt aber auch nix zum gegensteuern,
auf einen sonnigen heißen Tag
Alf-Fred
Hallo Alfred,
@ all,
echt deprimierend. Nur gut das ich im 1. Stock wohne :-)
Kommt jetzt der Split oder lösen wir uns einfach so auf?
lg Plaste
PS: Wenigstens spielt das Wetter mit
@ all,
echt deprimierend. Nur gut das ich im 1. Stock wohne :-)
Kommt jetzt der Split oder lösen wir uns einfach so auf?
lg Plaste
PS: Wenigstens spielt das Wetter mit
den Resplit heute bitte mit einer sehr positiven News begleiten,
dann könnte man aus dem Tal der Tränen herauskommen
dann könnte man aus dem Tal der Tränen herauskommen
Hallo Alfred,
heute Resplit?
Stand das irgend wo???
heute Resplit?
Stand das irgend wo???
Re-Split heute ,habe ich nicht gefunden. Die Hauptversammlung wurde auf heute den 25. Juli 2013 vertagt,
The adoption of CEL-SCI’s 2013 Non-Qualified Stock Option Plan, which provides that up to 20,000,000 shares of common stock may be issued upon the exercise of options granted pursuant to the plan, did not receive the required number of votes.
As a result, the annual shareholders’ meeting was adjourned to July 25, 2013, allowing stockholders additional time to vote on the adoption of the 2013 Non-Qualified Plan. The meeting will reconvene on that date at 10:30 a.m. at CEL-SCI’s corporate office, which is located at 8229 Boone Boulevard, Suite 802, Vienna, Virginia 22182.
The adoption of CEL-SCI’s 2013 Non-Qualified Stock Option Plan, which provides that up to 20,000,000 shares of common stock may be issued upon the exercise of options granted pursuant to the plan, did not receive the required number of votes.
As a result, the annual shareholders’ meeting was adjourned to July 25, 2013, allowing stockholders additional time to vote on the adoption of the 2013 Non-Qualified Plan. The meeting will reconvene on that date at 10:30 a.m. at CEL-SCI’s corporate office, which is located at 8229 Boone Boulevard, Suite 802, Vienna, Virginia 22182.
CEL-SCI and NIAID Publish Data Showing That CEL-SCI's LEAPS Technology Halted Progression of Lethal Influenza in Three Different Influenza Virus Strains, Including a Drug-Resistant and a 2009 Pandemic Flu Strain
http://www.nasdaq.com/press-release/cel-sci-and-niaid-publis…
Premarket
CVM $0.1995* +0.0315 + 18.75%
http://www.nasdaq.com/press-release/cel-sci-and-niaid-publis…
Premarket
CVM $0.1995* +0.0315 + 18.75%
Antwort auf Beitrag Nr.: 45.112.487 von binda am 25.07.13 11:54:41mit Re - Split meinte ich, dass auf der HV von gestern darüber abgestimmt wird ( ob er kommt )
aber mein " Schulenglisch " ist lange her,
......
(2)
subject to the determination of CEL-SCI's directors that a reverse split would be in the best interest of CEL-SCI's shareholders, the adoption of a reverse split of CEL-SCI's common stock. A condition of the reverse stock split is that the ratio of the reverse split will be determined by CEL-SCI's Board of Directors, provided that, in any case, the reverse split ratio will not be greater than 10 for 1. The Board of Directors may elect not to proceed with a stock split without further action by the shareholders;
Read more: http://www.nasdaq.com/press-release/cel-sci-corporation-anno…
aber mein " Schulenglisch " ist lange her,
......
(2)
subject to the determination of CEL-SCI's directors that a reverse split would be in the best interest of CEL-SCI's shareholders, the adoption of a reverse split of CEL-SCI's common stock. A condition of the reverse stock split is that the ratio of the reverse split will be determined by CEL-SCI's Board of Directors, provided that, in any case, the reverse split ratio will not be greater than 10 for 1. The Board of Directors may elect not to proceed with a stock split without further action by the shareholders;
Read more: http://www.nasdaq.com/press-release/cel-sci-corporation-anno…
starke Rally
Nur warum?
Nachbörslich auf 0,25 USD
Nachbörslich auf 0,25 USD
Hallo Plaste,
wollen wir mal hoffen, um nicht etwa den Kurs in eine optimale Position für einen möglichen Reverse-Split zu treiben.
Bei den letzten Kursrallys waren, wenn ich nicht irre, am Ende wohl immer irgendwelche Kapitalbeschaffungsmaßnahmen im Spiel, oder?
Schön wär's, wenn's mal eine wirklich positive News geben würde. Eine, auf der wir doch alle schon soooo lange warten.
bye
schlumpftrader
wollen wir mal hoffen, um nicht etwa den Kurs in eine optimale Position für einen möglichen Reverse-Split zu treiben.
Bei den letzten Kursrallys waren, wenn ich nicht irre, am Ende wohl immer irgendwelche Kapitalbeschaffungsmaßnahmen im Spiel, oder?
Schön wär's, wenn's mal eine wirklich positive News geben würde. Eine, auf der wir doch alle schon soooo lange warten.
bye
schlumpftrader
Danke ALF-FRED
Geert Kersten, Chief Executive Officer said, "During the past few months we have worked closely with our new CROs to accelerate enrollment in our Phase 3 head and neck cancer clinical trial.
We believe the changes we have made will allow them to enroll patients much faster and more cost-effectively. We are making considerable progress in advancing the study, with the exception of India, where new medical legislation has impacted clinical trial enrollment for all pharmaceutical companies, including the NIH.
There are proposals under consideration in the country to amend the law, which would allow CEL-SCI to resume enrollment of new patients there. In the interim, we have begun to develop plans in other Far Eastern countries, such as Thailand, Indonesia, Malaysia, Philippines; key investigators have already been identified in these countries in the event that India does not come on-line in a timely manner.
We are also currently in the process of adding over 40 clinical centers around the world, more than doubling the number of clinical trial sites that will be able to enroll subjects in our study.
By mid-August we will also have completely redesigned the electronic data software for the study to make it more user friendly to study personnel at the sites. Based on the foregoing we expect enrollment will accelerate beginning in September."
Geert Kersten, Chief Executive Officer said, "During the past few months we have worked closely with our new CROs to accelerate enrollment in our Phase 3 head and neck cancer clinical trial.
We believe the changes we have made will allow them to enroll patients much faster and more cost-effectively. We are making considerable progress in advancing the study, with the exception of India, where new medical legislation has impacted clinical trial enrollment for all pharmaceutical companies, including the NIH.
There are proposals under consideration in the country to amend the law, which would allow CEL-SCI to resume enrollment of new patients there. In the interim, we have begun to develop plans in other Far Eastern countries, such as Thailand, Indonesia, Malaysia, Philippines; key investigators have already been identified in these countries in the event that India does not come on-line in a timely manner.
We are also currently in the process of adding over 40 clinical centers around the world, more than doubling the number of clinical trial sites that will be able to enroll subjects in our study.
By mid-August we will also have completely redesigned the electronic data software for the study to make it more user friendly to study personnel at the sites. Based on the foregoing we expect enrollment will accelerate beginning in September."
kosten steigen und kein cash mehr
Und wir Deppen finanzieren deren Erhöhungen bzw. Verlängerungsjahre.
bye
schlumpftrader
bye
schlumpftrader
Antwort auf Beitrag Nr.: 45.369.595 von schlumpftrader am 02.09.13 15:28:49positiv denken- heute kann sie nicht fallen die Aktie - Feiertag !!!!
CEL-SCI Corporation (NYSE: CVM [FREE Stock Trend Analysis]) announces that the NYSE MKT (the “Exchange”) has accepted the Company's plan to bring itself into compliance with the Exchange's continued listing standards.
The Company previously received notice from the Exchange on July 18, 2013, indicating that the Company is not in compliance with Section 1003(a)(iv) of the Exchange's continued listing standards in the Company Guide. The Company was afforded the opportunity to submit a plan to regain compliance, and on August 19, 2013 the Company submitted its plan to the Exchange.
http://www.benzinga.com/news/13/09/3881787/cel-sci-says-nyse…
Antwort auf Beitrag Nr.: 45.376.075 von binda am 03.09.13 15:09:08ist das gut, oder bedeutet es nur Aufschub bis 30.09.2013 ?
Zitat von ALF-FRED: ist das gut, oder bedeutet es nur Aufschub bis 30.09.2013 ?
Der Plan, den Cel-Sci eingereicht hat, wurde von der NYSE MKT akzeptiert.
Ich sehe es positiv. Ob dies nur ein Aufschub ist, habe ich noch nicht herausgefunden.
If the Exchange
accepts the plan, then the Company may be able to continue its listing during
the plan period, during which time the Company will be subject to periodic
review to determine whether it is making progress consistent with the plan.
http://www.sec.gov/Archives/edgar/data/725363/00010048781300…
drüben gehts erst mal hoch
ich meinte den Auszug von der News auf der Yahoo seite
..................
On August 30, 2013, the Exchange notified the Company that it accepted the Company's plan of compliance and granted the Company an extension until September 30, 2013 to regain compliance with the continued listing standards. The Company will be subject to periodic review during the extension period. Failure to make progress consistent with the plan or to regain compliance with the continued listing standards by the end of the extension period could result in the Company being delisted from the NYSE MKT.
..................
On August 30, 2013, the Exchange notified the Company that it accepted the Company's plan of compliance and granted the Company an extension until September 30, 2013 to regain compliance with the continued listing standards. The Company will be subject to periodic review during the extension period. Failure to make progress consistent with the plan or to regain compliance with the continued listing standards by the end of the extension period could result in the Company being delisted from the NYSE MKT.
Zitat von ALF-FRED: ich meinte den Auszug von der News auf der Yahoo seite
..................
On August 30, 2013, the Exchange notified the Company that it accepted the Company's plan of compliance and granted the Company an extension until September 30, 2013 to regain compliance with the continued listing standards. The Company will be subject to periodic review during the extension period. Failure to make progress consistent with the plan or to regain compliance with the continued listing standards by the end of the extension period could result in the Company being delisted from the NYSE MKT.
Hatte ich noch nicht gesehen, Danke.
Bis zum 30.9. bleiben sie auf jeden Fall gelistet. In der Zeit muß Cel-Sci ihren Plan umsetzen, um die Anforderungen für ein Listing an der NYSE zu erfüllen. Dies wird in regelmäßigen Abständen überprüft werden. Sollte es keine Fortschritte, in der Umsetzung des Plans, in diesem gewährten Zeitraum geben, steht ein Delisting an.
Da die NYSE den Cel-sci-Plan akzeptiert und nicht direkt verworfen hat, scheinen die der Meinung zu sein, dass es machbar ist.
Verdammt wenig Zeit, bis zum 30.Sept.
Antwort auf Beitrag Nr.: 45.377.039 von binda am 03.09.13 16:47:11Dankeschön
Vorwurf an Cel-Sci:
CEL-SCI was deemed to
be noncompliant with certain continued listing standards of the Exchange as set
forth in Part 10 of the NYSE MKT Company Guide (the "Company Guide"). In
particular, based on the Company's quarterly report on Form 10-Q for the period
ended March 31, 2013, noncompliance was noted with respect to the requirement of
section 1003(a)(iv) of the Company Guide for NYSE MKT issuers. Additional
information and provisions regarding the NYSE MKT requirements are found in Part
10 of its company guide.
Hier die Spielregeln: NYSE MKT LLC Company Guide:
http://wallstreet.cch.com/mkt/companyguide/
CEL-SCI was deemed to
be noncompliant with certain continued listing standards of the Exchange as set
forth in Part 10 of the NYSE MKT Company Guide (the "Company Guide"). In
particular, based on the Company's quarterly report on Form 10-Q for the period
ended March 31, 2013, noncompliance was noted with respect to the requirement of
section 1003(a)(iv) of the Company Guide for NYSE MKT issuers. Additional
information and provisions regarding the NYSE MKT requirements are found in Part
10 of its company guide.
Hier die Spielregeln: NYSE MKT LLC Company Guide:
http://wallstreet.cch.com/mkt/companyguide/
Antwort auf Beitrag Nr.: 45.377.671 von binda am 03.09.13 17:46:12 bei mir steht nix, gibt's von dir eine Zusammenfassung ? Bitte !
Steht aber auch nichts Neues/ Anderes drin.
EXHIBIT 99
CEL-SCI CORPORATION
8229 Boone Boulevard, Suite 802 COMPANY CONTACT:
Vienna, VA 22182. USA Gavin de Windt
Telephone (703) 506-9460 CEL-SCI Corporation
www.cel-sci.com (703) 506-9460
CEL-SCI ANNOUNCES THAT NYSE MKT APPROVES PLAN
Vienna, VA, September 3, 2013 - CEL-SCI Corporation (NYSE MKT: CVM) announces that the NYSE MKT (the "Exchange") has accepted the Company's plan to bring itself into compliance with the Exchange's continued listing standards.
The Company previously received notice from the Exchange on July 18, 2013, indicating that the Company is not in compliance with Section 1003(a)(iv) of the Exchange's continued listing standards in the Company Guide. The Company was afforded the opportunity to submit a plan to regain compliance, and on August 19, 2013 the Company submitted its plan to the Exchange.
On August 30, 2013, the Exchange notified the Company that it accepted the Company's plan of compliance and granted the Company an extension until September 30, 2013 to regain compliance with the continued listing standards. The Company will be subject to periodic review during the extension period. Failure to make progress consistent with the plan or to regain compliance with the continued listing standards by the end of the extension period could result in the Company being delisted from the NYSE MKT.
About CEL-SCI Corporation
CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system. Its lead investigational therapy is Multikine (Leukocyte Interleukin, Injection), currently being studied in a pivotal global Phase III clinical trial. CEL-SCI is also investigating an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized patients and as a vaccine (CEL-2000) for Rheumatoid Arthritis (currently in preclinical testing) using its LEAPS technology platform. The investigational immunotherapy LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu, as CEL-SCI scientists are very concerned about the possible emergence of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.
When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended September 30, 2012. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Vielleicht klappts mit diesem ( dauert etwas, bis es sich öffnet):
http://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?F…
EXHIBIT 99
CEL-SCI CORPORATION
8229 Boone Boulevard, Suite 802 COMPANY CONTACT:
Vienna, VA 22182. USA Gavin de Windt
Telephone (703) 506-9460 CEL-SCI Corporation
www.cel-sci.com (703) 506-9460
CEL-SCI ANNOUNCES THAT NYSE MKT APPROVES PLAN
Vienna, VA, September 3, 2013 - CEL-SCI Corporation (NYSE MKT: CVM) announces that the NYSE MKT (the "Exchange") has accepted the Company's plan to bring itself into compliance with the Exchange's continued listing standards.
The Company previously received notice from the Exchange on July 18, 2013, indicating that the Company is not in compliance with Section 1003(a)(iv) of the Exchange's continued listing standards in the Company Guide. The Company was afforded the opportunity to submit a plan to regain compliance, and on August 19, 2013 the Company submitted its plan to the Exchange.
On August 30, 2013, the Exchange notified the Company that it accepted the Company's plan of compliance and granted the Company an extension until September 30, 2013 to regain compliance with the continued listing standards. The Company will be subject to periodic review during the extension period. Failure to make progress consistent with the plan or to regain compliance with the continued listing standards by the end of the extension period could result in the Company being delisted from the NYSE MKT.
About CEL-SCI Corporation
CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system. Its lead investigational therapy is Multikine (Leukocyte Interleukin, Injection), currently being studied in a pivotal global Phase III clinical trial. CEL-SCI is also investigating an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized patients and as a vaccine (CEL-2000) for Rheumatoid Arthritis (currently in preclinical testing) using its LEAPS technology platform. The investigational immunotherapy LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu, as CEL-SCI scientists are very concerned about the possible emergence of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.
When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended September 30, 2012. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Vielleicht klappts mit diesem ( dauert etwas, bis es sich öffnet):
http://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?F…
OK, ich hoffe cel.-sci bekommt das hin und Multikine wirkt !
Meine Tante ist gestern mit 79 Jahren ziemlich qualvoll gestorben.
2 mal hat sie es geschafft den Mundkrebs zu besiegen, jetzt war es das 3 mal wo er ausgebrochen war, nur noch einen halben Kiefer, künstliche Ernährung, Verbrennungen nach der Bestrahlung und noch einiges mehr, insgesamt hat es ca. 4 - 5 Jahre gedauert von der 1. Diagnose bis zum Tod.
Meine Tante ist gestern mit 79 Jahren ziemlich qualvoll gestorben.
2 mal hat sie es geschafft den Mundkrebs zu besiegen, jetzt war es das 3 mal wo er ausgebrochen war, nur noch einen halben Kiefer, künstliche Ernährung, Verbrennungen nach der Bestrahlung und noch einiges mehr, insgesamt hat es ca. 4 - 5 Jahre gedauert von der 1. Diagnose bis zum Tod.
Tut mir leid für deine Tante.
Wie sieht wohl der "Plan" aus? Hat da jemand was Genaueres gefunden?
Ich denke, dass jetzt der Re-Split kommt.
Angekündigt war er ja schon. 10:1
Zur Zeit 19 cent in USA = 1,90$ nach dem Split
Ob das ausreicht? Welche anderen Optionen gibt es, um ein Delisting zu verhindern?
Wie sieht wohl der "Plan" aus? Hat da jemand was Genaueres gefunden?
Ich denke, dass jetzt der Re-Split kommt.
Angekündigt war er ja schon. 10:1
Zur Zeit 19 cent in USA = 1,90$ nach dem Split
Ob das ausreicht? Welche anderen Optionen gibt es, um ein Delisting zu verhindern?
Antwort auf Beitrag Nr.: 45.378.235 von binda am 03.09.13 18:43:45ja , schön wäre es mal was von Seiten Cel. zu hören, ich gehe auch von 1 zu 10 aus, was dann kommt - keine Ahnung.
eventuell kommt was zum 30.09. , das in der Luft hängen zerrt ganz schön
meine Aktien zeigen - 70 % an ( nur Cel. ) der Rest läuft sehr gut
eventuell kommt was zum 30.09. , das in der Luft hängen zerrt ganz schön
meine Aktien zeigen - 70 % an ( nur Cel. ) der Rest läuft sehr gut
Hey, die hatten 2005 schon mal das gleiche Problem
Na dann sind die ja geübt in so was.
AMEX accepts CEL-SCI's Compliance Plan
August 14, 2005
http://baltimore.citybizlist.com/article/amex-accepts-cel-sc…
Na dann sind die ja geübt in so was.
AMEX accepts CEL-SCI's Compliance Plan
August 14, 2005
http://baltimore.citybizlist.com/article/amex-accepts-cel-sc…
Tagchen ,
also ich für meinen Teil werde den R/S sicher nicht mitmachen. Schnitt derzeit 0,205 US$ ( mit kleinem Verlust kann ich mal wieder leben - hab einiges an Vorderwasser hier )....dann lieber wieder einige Zeit nach R/S.
Die Erfahrung sagt mir nix gutes zu den Kursverläufen nach R/S.
Werd mein Glück dann erst wieder so 4- 6 Wochen danach probieren...falls es sich nach unten dnach bewegt...wennn nein gut für euch. ( wäre auch o.k ).
Bis dahin erst mal good Luck
also ich für meinen Teil werde den R/S sicher nicht mitmachen. Schnitt derzeit 0,205 US$ ( mit kleinem Verlust kann ich mal wieder leben - hab einiges an Vorderwasser hier )....dann lieber wieder einige Zeit nach R/S.
Die Erfahrung sagt mir nix gutes zu den Kursverläufen nach R/S.
Werd mein Glück dann erst wieder so 4- 6 Wochen danach probieren...falls es sich nach unten dnach bewegt...wennn nein gut für euch. ( wäre auch o.k ).
Bis dahin erst mal good Luck
http://www.finanznachrichten.de/nachrichten-2013-09/27950818…
CEL-SCI Corporation (NYSE MKT: CVM) announced today that following an audit of its Multikine manufacturing plant and laboratories by a European Union (EU) Qualified Person (QP), the CEL-SCI facilities were found to be in a high level of compliance with the Good Manufacturing Practices (GMP) Directives of the EU and the International Conference on Harmonization (ICH). This inspection follows a successful inspection by a different QP in late 2010.
The EU, unlike other countries included in CEL-SCI's ongoing Phase III trial, requires every lot or batch of medicinal product intended for use in a clinical trial that is being conducted within its member states to be released by a QP to ensure the product's safety and compliance with the EU Directives. Each QP must be certified individually by the EU regulatory body to become a QP and needs to have extensive training and an in-depth critical understanding of all the aspects associated with manufacturing and distribution of drug products. Penn Pharmaceutical Services Ltd, UK, which has conducted this QP Audit, is providing QP service to CEL-SCI for the clinical Lot certification, and is engaged in releasing the clinical lots of the investigational drug Multikine for use in the EU.
The most recent audit concluded that CEL-SCI appears a well-managed organization with a clear commitment to the quality of its product, having well qualified and trained staff, and that both the manufacturing and laboratory facilities are of high caliber and more than adequate for their intended purpose.
CEL-SCI Corporation (NYSE MKT: CVM) announced today that following an audit of its Multikine manufacturing plant and laboratories by a European Union (EU) Qualified Person (QP), the CEL-SCI facilities were found to be in a high level of compliance with the Good Manufacturing Practices (GMP) Directives of the EU and the International Conference on Harmonization (ICH). This inspection follows a successful inspection by a different QP in late 2010.
The EU, unlike other countries included in CEL-SCI's ongoing Phase III trial, requires every lot or batch of medicinal product intended for use in a clinical trial that is being conducted within its member states to be released by a QP to ensure the product's safety and compliance with the EU Directives. Each QP must be certified individually by the EU regulatory body to become a QP and needs to have extensive training and an in-depth critical understanding of all the aspects associated with manufacturing and distribution of drug products. Penn Pharmaceutical Services Ltd, UK, which has conducted this QP Audit, is providing QP service to CEL-SCI for the clinical Lot certification, and is engaged in releasing the clinical lots of the investigational drug Multikine for use in the EU.
The most recent audit concluded that CEL-SCI appears a well-managed organization with a clear commitment to the quality of its product, having well qualified and trained staff, and that both the manufacturing and laboratory facilities are of high caliber and more than adequate for their intended purpose.
CEL-SCI's manufacturing and laboratory operations now compliant with GMP requirements
PBR Staff Writer
Published 10 September 2013
CEL-SCI's Multikine manufacturing plant and laboratories are now compliant with the good manufacturing practices (GMP) requirements of the European Union (EU) and the International Conference on Harmonization (ICH), according to an audit conducted by an EU qualified person (QP).
UK-based Penn Pharmaceutical Services was responsible for conducting the latest audit of CEL-SCI's facilities and it follows a successful inspection by a different QP in late 2010.
Unlike other countries included in CEL-SCI's ongoing Phase III trial, the EU, requires every lot or batch of medicinal product intended for use in a clinical trial that is being conducted within its member states to be released by a QP to ensure the product's safety and compliance with the EU Directives.
In order to become a QP, one needs to be certified individually by the EU regulatory body and also have wide training and an in-depth critical understanding of all the aspects related to manufacturing and distribution of drug products.
Currently, Penn Pharmaceutical is providing QP service to CEL-SCI for the clinical lot certification, and is also responsible for releasing the clinical lots of the investigational drug Multikine for use in the EU.
CEL-SCI carries out research and development for improving the treatment of cancer and other diseases by using the immune system.
Using its LEAPS technology platform, the company is currently investigating an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized patients and as a vaccine (CEL-2000) for rheumatoid arthritis.
http://processandproduction.pharmaceutical-business-review.c…
PBR Staff Writer
Published 10 September 2013
CEL-SCI's Multikine manufacturing plant and laboratories are now compliant with the good manufacturing practices (GMP) requirements of the European Union (EU) and the International Conference on Harmonization (ICH), according to an audit conducted by an EU qualified person (QP).
UK-based Penn Pharmaceutical Services was responsible for conducting the latest audit of CEL-SCI's facilities and it follows a successful inspection by a different QP in late 2010.
Unlike other countries included in CEL-SCI's ongoing Phase III trial, the EU, requires every lot or batch of medicinal product intended for use in a clinical trial that is being conducted within its member states to be released by a QP to ensure the product's safety and compliance with the EU Directives.
In order to become a QP, one needs to be certified individually by the EU regulatory body and also have wide training and an in-depth critical understanding of all the aspects related to manufacturing and distribution of drug products.
Currently, Penn Pharmaceutical is providing QP service to CEL-SCI for the clinical lot certification, and is also responsible for releasing the clinical lots of the investigational drug Multikine for use in the EU.
CEL-SCI carries out research and development for improving the treatment of cancer and other diseases by using the immune system.
Using its LEAPS technology platform, the company is currently investigating an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized patients and as a vaccine (CEL-2000) for rheumatoid arthritis.
http://processandproduction.pharmaceutical-business-review.c…
Antwort auf Beitrag Nr.: 45.418.983 von binda am 10.09.13 13:52:41 irgendwie hilft es dem Kurs nicht, nur positive P III hilft noch und dann die Zulassung, ansonsten geht's dem Ende zu
seit 4 Jahren kennt der Kurs nur eine Richtung. Bin vor längerem mit Verlust raus. Und bin froh, aufgegeben zu haben. Aber wenn die nun doch Zulassung bekommen und verpartnern ...
Wann ist eigentlich FDA-Sitzung dazu?
Wann ist eigentlich FDA-Sitzung dazu?
Split 1 zu 10 ab 25.09.2013
Antwort auf Beitrag Nr.: 45.488.641 von ALF-FRED am 20.09.13 14:24:00http://www.nasdaq.com/press-release/cel-sci-corporation-anno…
Antwort auf Beitrag Nr.: 45.488.641 von ALF-FRED am 20.09.13 14:24:00Meinungen ???
Zitat von ALF-FRED: Meinungen ???
Um ein Delisting zu verhindern, wohl die einzige Möglichkeit.
Hatte ich hier vor einigen Tagen schon geschrieben.
Ich bleibe drin.
Geert Kersten, CEO of CEL-SCI stated, "Over the last few months we have had numerous discussions with investors, advisors and our board about our capital structure. In deciding to move forward with the reverse split we looked at many factors. One that swayed us in the end to move forward with the reverse split is that the capital market rules have changed a great deal since the financial crisis and the number of potential purchasers for a sub $1 stock has significantly decreased. We believe the resulting increase in share price will demonstrate the true value of CEL-SCI's common stock and broaden the appeal of our shares to investors, particularly institutional stockholders."
Eine so groß aufgestellte klinische Studie (wohl die größte), kostet enorm viel Geld. Cel-Sci sucht und hofft auf Geldgeber.
Cel-Sci has about 310 million shares outstanding, giving it a market capitalization of $53 million. The reverse split will cut the number of shares to about 31 million.
Cel-Sci lost $4.5 million in its fiscal third quarter. Research and development spending rose to $3.8 million as it expands Phase III clinical trials for Multikine to dozens of locations around the world.
In August, the company said it was looking for partners or other sources of funding to continue operations.
The reverse split will be effective at the market open Sept. 25.
Cel-Sci stock (NYSE MKT: CMV) was down 2 cents to 17 cents per share in Friday trading.
http://www.bizjournals.com/washington/blog/techflash/2013/09…
Cel-Sci has about 310 million shares outstanding, giving it a market capitalization of $53 million. The reverse split will cut the number of shares to about 31 million.
Cel-Sci lost $4.5 million in its fiscal third quarter. Research and development spending rose to $3.8 million as it expands Phase III clinical trials for Multikine to dozens of locations around the world.
In August, the company said it was looking for partners or other sources of funding to continue operations.
The reverse split will be effective at the market open Sept. 25.
Cel-Sci stock (NYSE MKT: CMV) was down 2 cents to 17 cents per share in Friday trading.
http://www.bizjournals.com/washington/blog/techflash/2013/09…
für mich total unverständlich wie man so mit seinen aktionären umgehen kann?statt man ein partner ins boot holt und der die firma dann mit geld versorgt.dann müßte man auch nicht immer so hirnlose kapitalerhöhungen machen......wir altaktionäre werden ja immmer mehr beschissen....wann unser wundermittel kommen soll steht in den sternen(wahrtscheinlich in athen).....
in meinem alten " steuerfreien " Depot bekomme ich dann eine halbe Aktie geschenkt, da die Aktienanzahl mit einer 5 endet
Antwort auf Beitrag Nr.: 45.490.817 von ALF-FRED am 20.09.13 18:50:09und die halbe wird dann steuerpflichtig
Na da bin ich aber froh das ich Anfang Sept. so ziemlich null / null erst mal raus bin...R/S sind keine guten Dinge....bin mal gespannt wie es danach läuft...erst wieder interessant wenn paar Wochen herum sind...behalte es auf Watch.
Viel Glück erst mal ( hoffe es wird nicht zu heftig für euch ) - schöner Mist was die da treiben....( obwohl war ja mit Ansage )
Viel Glück erst mal ( hoffe es wird nicht zu heftig für euch ) - schöner Mist was die da treiben....( obwohl war ja mit Ansage )
Pre-Market : 0.22 Up 0.0510 (30.18%) 8:01AM EDT - Nasdaq Real Time Price
ob die Gerüchteküche auf yahoo stimmt und der resplit mit einer postiven News unterstützt wird ?
mal sehen wie es morgen im Depot aussieht und ob es hier in Germany auch sofort umgesetzt wird, habe sowas noch nicht mitgemacht.
mal sehen wie es morgen im Depot aussieht und ob es hier in Germany auch sofort umgesetzt wird, habe sowas noch nicht mitgemacht.
Antwort auf Beitrag Nr.: 45.509.837 von ALF-FRED am 24.09.13 19:55:02dauerd im Regelfall...5 bis ca. 10 Handelstage...bis zur Einbuchung nach R/S...darin liegt ja immer die GEFAHR , schlimmste war mal bei Cord Blood...da hats 5 Wochen !!!! gedauert...von meinem Einsatz war danach nix mehr vorhanden...ausgelöscht.....
Alles kann , nichts muss.
Klar wenn der Kurs mal steigt ist es vielleicht besser nix machen zu können, allerdings hab ich das noch nie erlebt...ich hab viele...viele R/S erlebt...aber ich mach das nie wieder irgendwo mit wenn möglich...denn oft ist es halt so, danach gehts runter.
Viel Glück trotzdem, jetzt ist es eh egal.
Alles kann , nichts muss.
Klar wenn der Kurs mal steigt ist es vielleicht besser nix machen zu können, allerdings hab ich das noch nie erlebt...ich hab viele...viele R/S erlebt...aber ich mach das nie wieder irgendwo mit wenn möglich...denn oft ist es halt so, danach gehts runter.
Viel Glück trotzdem, jetzt ist es eh egal.
Bin mal gespannt wie es nach R/S läuft ...müssten heute ja die neuen Anteile im Handel sein
...und vor allem wann und viele neue Scheine kommen danach auf den Markt...letztendllich immer der Zweck von R/S....also los gehts mit 31 Mio Stücken, daß gilt es zu beobachten mittelfristig....kommen viele neue...sinkt der Kurs - einfache Rechnung .
Viel Glück allen Investierten !!!!!
*************************************************
VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation(NYSE MKT:CVM), a late-stage oncology company, announced that it is effecting a 1-for-10 reverse stock split of its common stock which will be effective for trading purposes as of the commencement of trading on September 25, 2013. As of that date, each 10 shares of issued and outstanding common stock and equivalents will be converted into 1 share of common stock. In addition, at the market open on September 25, 2013, the common stock will trade under a new CUSIP number 150837508 although the Company's ticker symbol, CVM, will remain unchanged.
The number of outstanding common shares will be reduced from 310,005,272 to approximately 31 million. The number of authorized shares and the par value per share will remain unchanged. No fractional shares will be issued in connection with the reverse stock split. Any fractional shares resulting from the reverse stock split will be rounded to the nearest whole share. The number of outstanding options and warrants will be adjusted accordingly, with outstanding options being reduced from 52,034,756 to approximately 5.2 million and outstanding warrants being reduced from 99,181,434 to approximately 9.9 million.
It is not necessary for stockholders to exchange their existing stock certificates for new stock certificates in connection with the reverse stock split although stockholders may do so if they wish. Please direct any questions you might have concerning the reverse stock split to your broker or our transfer agent Computershare Trust Company by calling (800) 962-4284.
Geert Kersten, CEO of CEL-SCI stated, "Over the last few months we have had numerous discussions with investors, advisors and our board about our capital structure. In deciding to move forward with the reverse split we looked at many factors. One that swayed us in the end to move forward with the reverse split is that the capital market rules have changed a great deal since the financial crisis and the number of potential purchasers for a sub $1 stock has significantly decreased. We believe the resulting increase in share price will demonstrate the true value of CEL-SCI's common stock and broaden the appeal of our shares to investors, particularly institutional stockholders."
Read more: http://www.nasdaq.com/press-release/cel-sci-corporation-anno…
Viel Glück allen Investierten !!!!!
*************************************************
VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation(NYSE MKT:CVM), a late-stage oncology company, announced that it is effecting a 1-for-10 reverse stock split of its common stock which will be effective for trading purposes as of the commencement of trading on September 25, 2013. As of that date, each 10 shares of issued and outstanding common stock and equivalents will be converted into 1 share of common stock. In addition, at the market open on September 25, 2013, the common stock will trade under a new CUSIP number 150837508 although the Company's ticker symbol, CVM, will remain unchanged.
The number of outstanding common shares will be reduced from 310,005,272 to approximately 31 million. The number of authorized shares and the par value per share will remain unchanged. No fractional shares will be issued in connection with the reverse stock split. Any fractional shares resulting from the reverse stock split will be rounded to the nearest whole share. The number of outstanding options and warrants will be adjusted accordingly, with outstanding options being reduced from 52,034,756 to approximately 5.2 million and outstanding warrants being reduced from 99,181,434 to approximately 9.9 million.
It is not necessary for stockholders to exchange their existing stock certificates for new stock certificates in connection with the reverse stock split although stockholders may do so if they wish. Please direct any questions you might have concerning the reverse stock split to your broker or our transfer agent Computershare Trust Company by calling (800) 962-4284.
Geert Kersten, CEO of CEL-SCI stated, "Over the last few months we have had numerous discussions with investors, advisors and our board about our capital structure. In deciding to move forward with the reverse split we looked at many factors. One that swayed us in the end to move forward with the reverse split is that the capital market rules have changed a great deal since the financial crisis and the number of potential purchasers for a sub $1 stock has significantly decreased. We believe the resulting increase in share price will demonstrate the true value of CEL-SCI's common stock and broaden the appeal of our shares to investors, particularly institutional stockholders."
Read more: http://www.nasdaq.com/press-release/cel-sci-corporation-anno…
Antwort auf Beitrag Nr.: 45.514.187 von Expertchen007 am 25.09.13 14:20:18zum Kurs...gehts da lang ::::: http://www.nasdaq.com/symbol/cvm/real-time
1000 % ....leck fett......öh.....
Cel-Sci Corporation Real Time Stock Quotes
CVM
$2.2
+1000%
Read more: http://www.nasdaq.com/symbol/cvm/real-time#ixzz2fuL8i8c9
Antwort auf Beitrag Nr.: 45.514.727 von binda am 25.09.13 15:40:17völlig normal nach R/S...ich sag Dir aber mal lieber nicht was ich da so kommen sehe auf 4 -8 Wochenbasis......
würde Dich nicht sehr beruhigen...ich mach das nur noch so das wenn ich einen WErt mit R/S habe,,,,alles raushaue und mit dem Restgeld später entsprechend mehr zukaufe....alles ander hilft selten...ich weiß das tut echt weh.
würde Dich nicht sehr beruhigen...ich mach das nur noch so das wenn ich einen WErt mit R/S habe,,,,alles raushaue und mit dem Restgeld später entsprechend mehr zukaufe....alles ander hilft selten...ich weiß das tut echt weh.
Antwort auf Beitrag Nr.: 45.514.793 von Expertchen007 am 25.09.13 15:47:42 wie recht du doch hast
das wars wohl,alle schon verkauft....da wird sich die kerstin aber freuen,mehrwert für die aktionäre
Zitat von ALF-FRED: wie recht du doch hast
Na ja war / ist leider immer absehbar...ich habs zu oft erlebt....geht auch mal wieder Hoch...nur die Frage ab welcher Basis....nun gut ich hab Zeit und stehe an der Seite....
bei W.O findet man das Cel- Sci Forum nicht mehr...musste über google reingehen..hab den Mod bereits informiert...
Bissle Aufheiterung :
seh gerade , die hat ja schon heftig abgegeben auf 0,134 vor R/S bzw. 1,34 US$ jetzt.....also der 1 US$ kann durchaus unterschritten werden...es sei denn die bringen endlich mal was positives an PR raus.
Wird wohl auch viel geshortet werdem nach so einem R/S ...da wird gut verdient dran...auch normal.
Wird wohl auch viel geshortet werdem nach so einem R/S ...da wird gut verdient dran...auch normal.
CEL-SCI Announces That NYSE MKT Granted an Extension to Regain Compliance
10/4/2013 8:30:00 AM - Business Wire
Read more: http://www.nasdaq.com/symbol/cvm#ixzz2gl4eBrcU
10/4/2013 8:30:00 AM - Business Wire
Read more: http://www.nasdaq.com/symbol/cvm#ixzz2gl4eBrcU
Zitat von Expertchen007: CEL-SCI Announces That NYSE MKT Granted an Extension to Regain Compliance
10/4/2013 8:30:00 AM - Business Wire
Read more: http://www.nasdaq.com/symbol/cvm#ixzz2gl4eBrcU
Oct 4, 2013, 10:34am EDT
Cel-Sci gets stock listing extension
Jeff Clabaugh
Broadcast/Web Reporter-
Washington Business Journal
Email | Twitter
Veinna-based Cel-Sci Corp., running worldwide late-stage clinical trials for its experimental head and neck cancer drug, has a little more time to gain stock listing compliance.
Cel-Sci says the NYSE MKT, formerly the American Stock Exchange, has granted the company an extension until Oct. 31 to regain compliance with the exchange's listings standards. It previously had until Sept. 30.
Cel-Sci is subject to a delisting because of sustained losses or a financial condition so impaired that it appears questionable as to whether it can continue operations, in the opinion of the Exchange, according to the listings section cited.
Cel-Sci lost $4.5 million in its fiscal third quarter on higher research and development expenses as it expands Phase III clinical trials for Multikine to dozens of locations around the world.
The company has said it is looking for partners or other sources of funding to continue operations.
CEl-Sci implemented a 1-for-10 reverse stock split last month.
Hoffentlich schaffen die das.
ansonsten passiert das:
Failure to make progress consistent with the plan or to regain compliance with the continued listing standards by the end of the extension period could result in the Company being delisted from the NYSE MKT.
Failure to make progress consistent with the plan or to regain compliance with the continued listing standards by the end of the extension period could result in the Company being delisted from the NYSE MKT.
ganz schöner Mist was da abgeht, und bis 2015 ist noch lang hin
wenn der 1 US$ nachhaltig fällt wrds halt eng im Listing, .....na ja dann gehts an die OTC...auch kein Weltuntergasng , aber auch nicht wirklich toll.
Sag ja kommt auf die Taktik an...Verluste realisieren und unten kaufen....dann halt wesentlich mehr + Steuervorteil ...kann auch ne Möglichkeit sein.
Aber jeder wie er möchte...ich hätt ja jetzt auch schon Minus 40 -45 % von Basis 0,206 US$ ( jetzt 2,06 US$ ) gehabt wenn ich gehalten hätte.
Das lohnt sich dann schon wieder tiefer einzusteigen, aber noch warte ich relaxt ab.
Sag ja kommt auf die Taktik an...Verluste realisieren und unten kaufen....dann halt wesentlich mehr + Steuervorteil ...kann auch ne Möglichkeit sein.
Aber jeder wie er möchte...ich hätt ja jetzt auch schon Minus 40 -45 % von Basis 0,206 US$ ( jetzt 2,06 US$ ) gehabt wenn ich gehalten hätte.
Das lohnt sich dann schon wieder tiefer einzusteigen, aber noch warte ich relaxt ab.
CEL-SCI Corporation (NYSE: CVM [FREE Stock Trend Analysis]) today announced that it has signed a Cooperative Research and Development Agreement (CRADA) with the Naval Medical Center, San Diego. Pursuant to this agreement, the US Naval Medical Center, San Diego will conduct a Human Subjects Institutional Review Board approved Phase I dose escalation study of CEL-SCI's investigational immunotherapy Multikine (Leukocyte Interleukin, Injection) in HIV/HPV co-infected men and women with peri-anal warts. CEL-SCI will contribute the investigational study drug Multikine and will retain all rights to any currently owned technology and will have the right to exclusively license any new technology developed from the collaboration. CEL-SCI is supporting the project by providing Multikine and funding for laboratory studies.
Anal and genital warts are commonly associated with the Human Papilloma Virus, the most common sexually transmitted disease. Men and women with a history of anogenital warts have a 30 fold increased risk of anal cancer. Persistent HPV infection in the anal region is thought to be responsible for up to 80% of anal cancers. HPV is a significant health problem in the HIV infected population as individuals are living longer as a result of greatly improved HIV medications.
The purpose of this dose escalation study is to evaluate the safety and clinical impact of Multikine as a treatment of peri-anal warts and assess the effect on anal intraepithelial dysplasia (AIN) in HIV/HPV co-infected men and women. Five participants will be treated with Multikine injections around the peri-anal warts at the lower dose for 5 days/week for 2 weeks, off 2 weeks, then 5 days per week for two more 2 weeks. If no serious adverse events are noted, 10 more patients will receive the higher dose of Multikine in the same manner. The study is open to adult HIV positive men and women that are eligible for medical care from the Naval Medical Center San Diego.
Multikine is being given to the HIV/HPV co-infected patients with peri-anal warts because promising early results were seen in another Institutional Review Board approved Multikine Phase I study conducted at the University of Maryland. In this study, investigational therapy Multikine was given to HIV/HPV co-infected women with cervical dysplasia resulting in visual and histological evidence of clearance of lesions. Furthermore, elimination of a number of HPV strains was determined by in situ polymerase chain reaction (PCR) performed on tissue biopsy collected before and after Multikine treatment. As reported by the study investigators, the study volunteers all appeared to tolerate the treatment with no reported serious adverse events.
The treatment regimen for the study of up to 15 HIV/HPV co-infected patient volunteers with peri-anal warts to be conducted by Naval Medical Center San Diego will be identical to the regimen that was used in the Multikine cervical study in HIV/HPV co-infected patient volunteers.
The Naval Medical Center San Diego, a referral center of excellence for HIV/AIDS care of active duty, family members, and retired individuals since the start of the HIV epidemic in the 1980s, has conducted over 30 HIV/AIDS human subjects approved clinical research protocols to advance clinical patient care. The Principle Investigator on this Phase I study is John D. Malone MD, MPH, Infectious Diseases Staff Physician, Naval Medical Center San Diego. This Cooperative Research and Development Agreement to assess Multikine Immunotherapy in HIV/HPV co-infected volunteers with peri-anal warts will be beneficial to advance clinical medicine. By entering into this CRADA, NMCSD does not directly or indirectly endorse any product or service provided, or to be provided, by CEL-SCI, its successors, assignees, or licensees.
http://www.benzinga.com/news/13/10/3971214/cel-sci-reports-c…
Anal and genital warts are commonly associated with the Human Papilloma Virus, the most common sexually transmitted disease. Men and women with a history of anogenital warts have a 30 fold increased risk of anal cancer. Persistent HPV infection in the anal region is thought to be responsible for up to 80% of anal cancers. HPV is a significant health problem in the HIV infected population as individuals are living longer as a result of greatly improved HIV medications.
The purpose of this dose escalation study is to evaluate the safety and clinical impact of Multikine as a treatment of peri-anal warts and assess the effect on anal intraepithelial dysplasia (AIN) in HIV/HPV co-infected men and women. Five participants will be treated with Multikine injections around the peri-anal warts at the lower dose for 5 days/week for 2 weeks, off 2 weeks, then 5 days per week for two more 2 weeks. If no serious adverse events are noted, 10 more patients will receive the higher dose of Multikine in the same manner. The study is open to adult HIV positive men and women that are eligible for medical care from the Naval Medical Center San Diego.
Multikine is being given to the HIV/HPV co-infected patients with peri-anal warts because promising early results were seen in another Institutional Review Board approved Multikine Phase I study conducted at the University of Maryland. In this study, investigational therapy Multikine was given to HIV/HPV co-infected women with cervical dysplasia resulting in visual and histological evidence of clearance of lesions. Furthermore, elimination of a number of HPV strains was determined by in situ polymerase chain reaction (PCR) performed on tissue biopsy collected before and after Multikine treatment. As reported by the study investigators, the study volunteers all appeared to tolerate the treatment with no reported serious adverse events.
The treatment regimen for the study of up to 15 HIV/HPV co-infected patient volunteers with peri-anal warts to be conducted by Naval Medical Center San Diego will be identical to the regimen that was used in the Multikine cervical study in HIV/HPV co-infected patient volunteers.
The Naval Medical Center San Diego, a referral center of excellence for HIV/AIDS care of active duty, family members, and retired individuals since the start of the HIV epidemic in the 1980s, has conducted over 30 HIV/AIDS human subjects approved clinical research protocols to advance clinical patient care. The Principle Investigator on this Phase I study is John D. Malone MD, MPH, Infectious Diseases Staff Physician, Naval Medical Center San Diego. This Cooperative Research and Development Agreement to assess Multikine Immunotherapy in HIV/HPV co-infected volunteers with peri-anal warts will be beneficial to advance clinical medicine. By entering into this CRADA, NMCSD does not directly or indirectly endorse any product or service provided, or to be provided, by CEL-SCI, its successors, assignees, or licensees.
http://www.benzinga.com/news/13/10/3971214/cel-sci-reports-c…
ich weiß nicht was ich von der Nachricht halten soll, entweder gut weil ein neues Einsatzgebiet für Multikine ausprobiert wird, oder schlecht weil es am Hals nicht die gewünschten Ergebnisse bringt und zuviel von dem Zeugs über ist .
na hier bei WO wird der letzte Handel am 24.09. angegeben.
Wenn ich recht informiert bin, gab es einen R/S, somit neue Wertpapierkennnummer. Hast du die? dann verlink mal und diskutier da weiter
Wenn ich recht informiert bin, gab es einen R/S, somit neue Wertpapierkennnummer. Hast du die? dann verlink mal und diskutier da weiter
4:06PM CEL-SCI Corp announces proposed public offering of common stock and warrants; size not disclosed (CVM) 1.24 +0.03 : CVM announced that it intends to offer and sell common stock and warrants, subject to market and other conditions, in an underwritten public offering. Co intends to use the net proceeds of the offering for general corporate purposes, including working capital and operational purposes, and including product development. Chardan Capital Markets is acting as sole bookrunner for the offering and Laidlaw & Company is acting as co-manager on the deal.
Antwort auf Beitrag Nr.: 45.584.905 von ALF-FRED am 08.10.13 07:13:48 und after hours rauschts im Keller !!!
Ja Du bist nicht zu beneiden
Kaum ist der R/S durch folgt eine KE
Beobachte den Pick schon lange...heftig was da abgeht !
Kaum ist der R/S durch folgt eine KE
Beobachte den Pick schon lange...heftig was da abgeht !
Was jetzt auch noch ne KE ?? ??? Na das wäre ja tötlich..,.saubere Verwässerung dann .
Expertchen007
schrieb am 08.10.13 21:01:48
Beitrag Nr.4
(45.590.653)
Antwort
Zitat
Zitat von ALF-FRED
mir fehlen echt die Worte
*********************************************
ging ja leider schneller als ich dachte unter den 1 US$......na dann gute Nacht ....bin aber immer noch lange nicht bereit wieder reinzugehen...denk bei unter 0,50 $ könnt ich es eventuell mal riskieren.
Schade für euch Longs...aber es war ja mit Ansage...wer meiner Berrechnung gefolgt war...kann bereits jetzt...fürs Restgeld..Anteile x 2 erwerben.....ist ja eventuell auch was Wert in Zukunft oder halt nix...aber wenigstens die doppelten Anteile + Steurvorteil..aus dem Verlustverkauf..kann sich gut Rechnen..hatte ich schön öfters so gemacht bei anderen Projekten...klappt natürlich nicht immer.
Viel Glück erst mal noch...wegen mir 500 % rauf...dann halt ohne mich
schrieb am 08.10.13 21:01:48
Beitrag Nr.4
(45.590.653)
Antwort
Zitat
Zitat von ALF-FRED
mir fehlen echt die Worte
*********************************************
ging ja leider schneller als ich dachte unter den 1 US$......na dann gute Nacht ....bin aber immer noch lange nicht bereit wieder reinzugehen...denk bei unter 0,50 $ könnt ich es eventuell mal riskieren.
Schade für euch Longs...aber es war ja mit Ansage...wer meiner Berrechnung gefolgt war...kann bereits jetzt...fürs Restgeld..Anteile x 2 erwerben.....ist ja eventuell auch was Wert in Zukunft oder halt nix...aber wenigstens die doppelten Anteile + Steurvorteil..aus dem Verlustverkauf..kann sich gut Rechnen..hatte ich schön öfters so gemacht bei anderen Projekten...klappt natürlich nicht immer.
Viel Glück erst mal noch...wegen mir 500 % rauf...dann halt ohne mich
übel...na ja irgenwann gehts auch mal vorüber.....Kurs vor R/S 0,083 US ( jetzt 0,83 )...glaub das ist Altzeittief oder ????
Cel-Sci Corporation Real Time Stock Quotes
CVM
$0.83
*
-0.41
negative
[b]-33.06%[/b]
*Real-Time - data as of 10/8/2013
Read more: http://www.nasdaq.com/symbol/cvm/real-time#ixzz2hAAooeU1
Cel-Sci Corporation Real Time Stock Quotes
CVM
$0.83
*
-0.41
negative
[b]-33.06%[/b]
*Real-Time - data as of 10/8/2013
Read more: http://www.nasdaq.com/symbol/cvm/real-time#ixzz2hAAooeU1
ja laut Chart max..ist es Altzeittief...aber so richtig Tief !!!!
http://www.nasdaq.com/symbol/cvm/interactive-chart?timeframe…
schlimmer sind da nur meine Uranwerte...die sind allesamt auf Altzeitief !!!
http://www.nasdaq.com/symbol/cvm/interactive-chart?timeframe…
schlimmer sind da nur meine Uranwerte...die sind allesamt auf Altzeitief !!!
bin jetzt schon seit 7 jahren dabei - es ist doch immer wieder schön zu sehen,
wie die kleinen hier abgezockt werden! nach dem r/s nur noch 10% der stückzahlen und bald wieder bei 0,20 super
wie die kleinen hier abgezockt werden! nach dem r/s nur noch 10% der stückzahlen und bald wieder bei 0,20 super
Zitat von rk1901: bin jetzt schon seit 7 jahren dabei - es ist doch immer wieder schön zu sehen,
wie die kleinen hier abgezockt werden! nach dem r/s nur noch 10% der stückzahlen und bald wieder bei 0,20 super
Glaub da musste dann von ganz vorn anfangen...KE und R/S gerechnet bleibt ja da nix übrig vom alten Einsatz...mir auch schon passiert
Oct 15, 2013, 10:15am EDT
Cel-Sci, partner to advance HIV/HPV drug
Jeff Clabaugh
Broadcast/Web Reporter-
Washington Business Journal
Vienna-based Cel-Sci, already running late-stage clinical trials for its experimental head and neck cancer drug Multikine, will advance studies of the same drug in treating women infected with both HIV and HPV who have cervical dysplasia.
Ergomed Clinical Research Ltd. will fund half of the clinical and regulatory costs for developing the drug in a profit sharing agreement.
Ergomed is already one of Cel-Sci's development partners in Multikine's head and neck cancer research and took over the largest part of the Phase III study in April.
Cel-Sci, (NYSE MKT: CVM) which lost $4.5 million in its fiscal third quarter, has been looking for partners or other sources of funding to continue operations.
http://www.bizjournals.com/washington/blog/techflash/2013/10…
Cel-Sci, partner to advance HIV/HPV drug
Jeff Clabaugh
Broadcast/Web Reporter-
Washington Business Journal
Vienna-based Cel-Sci, already running late-stage clinical trials for its experimental head and neck cancer drug Multikine, will advance studies of the same drug in treating women infected with both HIV and HPV who have cervical dysplasia.
Ergomed Clinical Research Ltd. will fund half of the clinical and regulatory costs for developing the drug in a profit sharing agreement.
Ergomed is already one of Cel-Sci's development partners in Multikine's head and neck cancer research and took over the largest part of the Phase III study in April.
Cel-Sci, (NYSE MKT: CVM) which lost $4.5 million in its fiscal third quarter, has been looking for partners or other sources of funding to continue operations.
http://www.bizjournals.com/washington/blog/techflash/2013/10…
Zitat von ALF-FRED: http://www.nasdaq.com/press-release/cel-sci-regains-listing-…
Was das betrifft also wieder alles OK. Ein kleiner Trost
CEL-SCI Corporation(NYSE MKT:CVM) today announced that it has received notification from NYSE Regulation dated October 17, 2013 that the Company is now considered to have regained compliance with the listing requirements of the NYSE MKT LLC (the "Exchange") Company Guide.
News interessieren keinen mehr, den Kurs schon gar nicht !!!!!
Antwort auf Beitrag Nr.: 45.666.451 von ALF-FRED am 21.10.13 18:12:17ich meine die News von heute 21.10.2013
Zitat von ALF-FRED: http://www.nasdaq.com/press-release/cel-sci-and-ergomed-sign…
Geert Kersten, Chief Executive Officer of CEL-SCI said, "We believe that if the data from the studies in HIV/HPV co-infected men and women with anal warts meet our expectations, this may represent a shorter clinical development route for Multikine which could possibly enable the submission of a marketing application before completion of our ongoing Phase III clinical trial for head and neck cancer. The addition of Ergomed as a committed co-development partner to the combined efforts of CEL-SCI and the US Navy will be extremely helpful and will potentially save us a lot of time during the clinical development process."
Geldprobleme wie immer,hab sie vor ein paar wochen einmal noch zu 1,50 bzw 1,30 verkauft.ein tag später stand sie ja bei 0,86....warte nochmal ein paar kapitalerhöhungen ab,da mal schauen ob sie sich wieder 0,20 und 0,50 cent ein pendelt.....nicht zu vergessen,wir hatten ja ein kapitalschnitt von 1 zu 10
Zitat von ALF-FRED: schau mal an ?
http://finance.yahoo.com/news/cel-sci-announces-initiation-a…
50 Millionen ? Könnte Cel-Sci gut gebrauchen.
VIENNA, Va.--(BUSINESS WIRE)--
CEL-SCI Corporation (NYSE MKT: CVM) announced today that it has received approval from the Health Protection Administration, Ministry of Health, of the Croatian Republic to begin enrollment of subjects into the Phase III clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection). Croatia is the ninth country into which CEL-SCI has expanded its global Phase III trial. The trial is expected to be conducted in about 100 clinical centers worldwide. CEL-SCI expects to enroll approximately 40 patients in Croatia through four clinical centers.
CEL-SCI plans to accelerate enrollment in its Phase III clinical trial for Multikine by adding a large number of clinical centers in the eight countries where approval to start the trial was previously received and by adding new countries and centers around the world. These new centers are in addition to the Phase III clinical centers run by CEL-SCI's partners (Teva, Israel and Orient Europharma, Taiwan).
“We are truly seeing major progress in advancing our study since engaging the two new CROs Ergomed and Aptiv Solutions, following our dismissal of the prior CRO that was managing the study, inVentiv, for lack of performance. Ergomed, which is responsible for about 95% of the patient enrollment in the trial, has invested $10 million of its own funds in the Phase III trial and, since then, has invested another $6 million in two other Multikine collaborations with CEL-SCI. Both CROs understand the potential of our science and share our vision, commitment, and diligence to bring this groundbreaking immunotherapy to market,” stated CEL-SCI CEO Geert Kersten.
On November 5, 2013 CEL-SCI announced that a second interim review of the safety data from its open label, randomized, controlled, pivotal Phase III study of Multikine investigational new drug immunotherapy was completed by the Independent Data Monitoring Committee (IDMC). The Committee, which is comprised of world class leaders in head and neck cancer, concluded that the data raised no safety concerns, and recommended that the Phase III study continue unmodified.
The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant, 10% improvement in overall survival of enrolled patients who are treated with Multikine plus Standard of Care (SOC) vs. subjects who are treated with SOC only. Multikine is intended to create an anti-tumor immune response to reduce local / regional tumor recurrence and thereby increase the survival of these patients.
CEL-SCI's lead investigational therapy, Multikine, is the first immunotherapeutic agent being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved by regulatory agencies (e.g. FDA) for use following completion of our clinical development program, Multikine would become an additional and different kind of therapy in the fight against cancer: one that aims to employ our body's natural ability to fight tumors.
On October 31, 2013 CEL-SCI announced that it had initiated an arbitration claim against inVentiv Clinical, LLC (f/k/a PharmaNet, LLC and PharmaNet GmbH (f/k/a PharmaNet AG)). CEL-SCI initially retained inVentiv Clinical to conduct the Phase III clinical trial of Multikine. CEL-SCI terminated inVentiv in or about April 2013 and replaced it with two clinical research organizations, Aptiv Solutions, Inc. and Ergomed Clinical Research Ltd. CEL-SCI's arbitration claim is initiated under the Commercial Rules of the American Arbitration Association alleging (i) breach of contract, (ii) fraud in the inducement, and (iii) common law fraud, and seeks at least $50 million in damages.
http://www.benzinga.com/pressreleases/13/11/b4072488/cel-sci…
CEL-SCI Corporation (NYSE MKT: CVM) announced today that it has received approval from the Health Protection Administration, Ministry of Health, of the Croatian Republic to begin enrollment of subjects into the Phase III clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection). Croatia is the ninth country into which CEL-SCI has expanded its global Phase III trial. The trial is expected to be conducted in about 100 clinical centers worldwide. CEL-SCI expects to enroll approximately 40 patients in Croatia through four clinical centers.
CEL-SCI plans to accelerate enrollment in its Phase III clinical trial for Multikine by adding a large number of clinical centers in the eight countries where approval to start the trial was previously received and by adding new countries and centers around the world. These new centers are in addition to the Phase III clinical centers run by CEL-SCI's partners (Teva, Israel and Orient Europharma, Taiwan).
“We are truly seeing major progress in advancing our study since engaging the two new CROs Ergomed and Aptiv Solutions, following our dismissal of the prior CRO that was managing the study, inVentiv, for lack of performance. Ergomed, which is responsible for about 95% of the patient enrollment in the trial, has invested $10 million of its own funds in the Phase III trial and, since then, has invested another $6 million in two other Multikine collaborations with CEL-SCI. Both CROs understand the potential of our science and share our vision, commitment, and diligence to bring this groundbreaking immunotherapy to market,” stated CEL-SCI CEO Geert Kersten.
On November 5, 2013 CEL-SCI announced that a second interim review of the safety data from its open label, randomized, controlled, pivotal Phase III study of Multikine investigational new drug immunotherapy was completed by the Independent Data Monitoring Committee (IDMC). The Committee, which is comprised of world class leaders in head and neck cancer, concluded that the data raised no safety concerns, and recommended that the Phase III study continue unmodified.
The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant, 10% improvement in overall survival of enrolled patients who are treated with Multikine plus Standard of Care (SOC) vs. subjects who are treated with SOC only. Multikine is intended to create an anti-tumor immune response to reduce local / regional tumor recurrence and thereby increase the survival of these patients.
CEL-SCI's lead investigational therapy, Multikine, is the first immunotherapeutic agent being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved by regulatory agencies (e.g. FDA) for use following completion of our clinical development program, Multikine would become an additional and different kind of therapy in the fight against cancer: one that aims to employ our body's natural ability to fight tumors.
On October 31, 2013 CEL-SCI announced that it had initiated an arbitration claim against inVentiv Clinical, LLC (f/k/a PharmaNet, LLC and PharmaNet GmbH (f/k/a PharmaNet AG)). CEL-SCI initially retained inVentiv Clinical to conduct the Phase III clinical trial of Multikine. CEL-SCI terminated inVentiv in or about April 2013 and replaced it with two clinical research organizations, Aptiv Solutions, Inc. and Ergomed Clinical Research Ltd. CEL-SCI's arbitration claim is initiated under the Commercial Rules of the American Arbitration Association alleging (i) breach of contract, (ii) fraud in the inducement, and (iii) common law fraud, and seeks at least $50 million in damages.
http://www.benzinga.com/pressreleases/13/11/b4072488/cel-sci…
0,77 US$ : 10 = 0,08 US$ vor R/S gerundet......mein lieber Schorsch...das ist brutal.
Bin immer noch am Seitenrand, vermutlich noch länger.
http://www.nasdaq.com/symbol/cvm/stock-chart?intraday=off&ti…
Bin immer noch am Seitenrand, vermutlich noch länger.
http://www.nasdaq.com/symbol/cvm/stock-chart?intraday=off&ti…
jetzt geht das Lichtlein aus
Das nennt man vertrauensbildene Massnahme.
Nachbörslich und unkommentiert so etwas rauszuhauen.
Alles nur Geschwafel in dem Brief an die Aktionäre,
Ich verstehe das nicht. Haben für mindestens 1 Jahr genug Geld.
Warum das jetzt?
Nachbörslich und unkommentiert so etwas rauszuhauen.
Alles nur Geschwafel in dem Brief an die Aktionäre,
Ich verstehe das nicht. Haben für mindestens 1 Jahr genug Geld.
Warum das jetzt?
Ja Wahnsinn !!!!
Geld
0,129
€
5.000
|
Man was bin ich da froh stillgehalten zu haben..ne ich bleib immer noch weg....keine Ahnung wo das endet.
Cel-Sci Corporation After Hours Trading
CVM
$.50
*
0.21
negative
-29.58%
Read more: http://www.nasdaq.com/symbol/cvm/after-hours#ixzz…
Geld
0,129
€
5.000
|
Man was bin ich da froh stillgehalten zu haben..ne ich bleib immer noch weg....keine Ahnung wo das endet.
Cel-Sci Corporation After Hours Trading
CVM
$.50
*
0.21
negative
-29.58%
Read more: http://www.nasdaq.com/symbol/cvm/after-hours#ixzz…
CEL-SCI Corporation Announces Proposed Public Offering of Common Stock and Warrants
By Business Wire, December 18, 2013, 04:22:00 PM EDT
Read more: http://www.nasdaq.com/press-release/celsci-corporation-annou…
By Business Wire, December 18, 2013, 04:22:00 PM EDT
Read more: http://www.nasdaq.com/press-release/celsci-corporation-annou…
CEL-SCI Corporation Prices $3.0 Million Public Offering of Common Stock and Warrants
By Business Wire, December 19, 2013, 09:16:00 AM EDT
Read more: http://www.nasdaq.com/press-release/celsci-corporation-price…
VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE MKT:CVM), a late-stage oncology company, today announced that it has priced an underwritten public offering of units of common stock and warrants at a price of $0.63 per unit for gross proceeds of $3,000,000, prior to deducting underwriting discounts and commissions and offering expenses of the Company. Each unit consists of one share of common stock and a warrant to purchase one share of common stock. The common stock and warrants will separate immediately. The warrants are immediately exercisable, expire October 11, 2018 and have an exercise price of $1.25. The warrants have been approved for an unpriced quotation on the OTC Bulletin Board under the symbol "CSCIW," however no market for the warrants has developed as of the date of this press release. The offering is expected to close on or about December 24, 2013, subject to the satisfaction of customary closing conditions. CEL-SCI has also granted the underwriters a 45-day option to purchase up to an additional 10% of the shares and/or warrants to cover overallotments.
CEL-SCI intends to use the net proceeds of the offering for its Phase III clinical trial, other research and development, and general and administrative expenses.
Laidlaw & Company (UK) Ltd. is acting as sole book-running manager for the offering. Dawson James Securities, Inc. is acting as co-manager for the offering.
Read more: http://www.nasdaq.com/press-release/celsci-corporation-price…
By Business Wire, December 19, 2013, 09:16:00 AM EDT
Read more: http://www.nasdaq.com/press-release/celsci-corporation-price…
VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE MKT:CVM), a late-stage oncology company, today announced that it has priced an underwritten public offering of units of common stock and warrants at a price of $0.63 per unit for gross proceeds of $3,000,000, prior to deducting underwriting discounts and commissions and offering expenses of the Company. Each unit consists of one share of common stock and a warrant to purchase one share of common stock. The common stock and warrants will separate immediately. The warrants are immediately exercisable, expire October 11, 2018 and have an exercise price of $1.25. The warrants have been approved for an unpriced quotation on the OTC Bulletin Board under the symbol "CSCIW," however no market for the warrants has developed as of the date of this press release. The offering is expected to close on or about December 24, 2013, subject to the satisfaction of customary closing conditions. CEL-SCI has also granted the underwriters a 45-day option to purchase up to an additional 10% of the shares and/or warrants to cover overallotments.
CEL-SCI intends to use the net proceeds of the offering for its Phase III clinical trial, other research and development, and general and administrative expenses.
Laidlaw & Company (UK) Ltd. is acting as sole book-running manager for the offering. Dawson James Securities, Inc. is acting as co-manager for the offering.
Read more: http://www.nasdaq.com/press-release/celsci-corporation-price…
http://www.sec.gov/Archives/edgar/data/725363/00013544881300…
Results of Operations
Fiscal 2013
During the year ended September 30, 2013, grant and other income decreased by $95,027 compared to the year ended September 30, 2012. The decrease is primarily due to the timing of drug shipments to supply the Company’s partner in Taiwan during fiscal year 2013. Shipment of drug was made in October 2013 to resupply the partner.
During the year ended September 30, 2013, research and development expenses increased by $2,312,354 compared to the year ended September 30, 2012. CEL-SCI is continuing the Phase III clinical trial and research and development fluctuates based on the activity level of the clinical trial.
During the year ended September 30, 2013, general and administrative expenses increased by $387,399, compared to the year ended September 30, 2012. This increase is primarily due to the increased cost of employee options.
During the year ended September 30, 2013, CEL-SCI recorded a derivative gain of $10,750,666. For the year ended September 30, 2012, CEL-SCI recorded a derivative gain of $1,911,683. This variation was the result of the change in fair value of the derivative liabilities during the period which was caused by fluctuations in the share price of CEL-SCI’s common stock.
Interest expense was $170,423 during the year ended September 30, 2013, and consisted primarily of interest expense on the loan from CEL-SCI’s president of $165,609 and interest on a capital lease. Interest expense was $262,214 for the year ended September 30, 2012 and consisted of interest expense on the loan from CEL-SCI’s president of $165,609 and interest on the convertible notes of $96,605.
Results of Operations
Fiscal 2013
During the year ended September 30, 2013, grant and other income decreased by $95,027 compared to the year ended September 30, 2012. The decrease is primarily due to the timing of drug shipments to supply the Company’s partner in Taiwan during fiscal year 2013. Shipment of drug was made in October 2013 to resupply the partner.
During the year ended September 30, 2013, research and development expenses increased by $2,312,354 compared to the year ended September 30, 2012. CEL-SCI is continuing the Phase III clinical trial and research and development fluctuates based on the activity level of the clinical trial.
During the year ended September 30, 2013, general and administrative expenses increased by $387,399, compared to the year ended September 30, 2012. This increase is primarily due to the increased cost of employee options.
During the year ended September 30, 2013, CEL-SCI recorded a derivative gain of $10,750,666. For the year ended September 30, 2012, CEL-SCI recorded a derivative gain of $1,911,683. This variation was the result of the change in fair value of the derivative liabilities during the period which was caused by fluctuations in the share price of CEL-SCI’s common stock.
Interest expense was $170,423 during the year ended September 30, 2013, and consisted primarily of interest expense on the loan from CEL-SCI’s president of $165,609 and interest on a capital lease. Interest expense was $262,214 for the year ended September 30, 2012 and consisted of interest expense on the loan from CEL-SCI’s president of $165,609 and interest on the convertible notes of $96,605.
Liquidity and Capital Resources
CEL-SCI has had only limited revenues from operations since its inception in March 1983. CEL-SCI has relied upon capital generated from the public and private offerings of its common stock and convertible notes. In addition, CEL-SCI has utilized short-term loans to meet its capital requirements. Capital raised by CEL-SCI has been expended primarily to acquire an exclusive worldwide license to use, and later purchase, certain patented and unpatented proprietary technology and know-how relating to the human immunological defense system. Capital has also been used for patent applications, debt repayment, research and development, administrative costs, and the construction of CEL-SCI’s laboratory facilities. CEL-SCI does not anticipate realizing significant revenues until it enters into licensing arrangements regarding its technology and know-how or until it receives regulatory approval to sell its products (which could take a number of years). As a result CEL-SCI has been dependent upon the proceeds from the sale of its securities to meet all of its liquidity and capital requirements and anticipates having to do so in the future. During fiscal year 2013 and 2012, CEL-SCI raised net proceeds of approximately $9,800,000 and $17,000,000, respectively, through the sale of stock and exercise of outstanding warrants. On October 11, 2013, CEL-SCI raised net proceeds of approximately $16,400,000 through the sale of stock and warrants in a public offering.
CEL-SCI will be required to raise additional capital or find additional long-term financing in order to continue with its research efforts. The ability of CEL-SCI to complete the necessary clinical trials and obtain FDA approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately, CEL-SCI must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. CEL-SCI believes that it has enough capital to support its operations for more than the next twelve months.
CEL-SCI has had only limited revenues from operations since its inception in March 1983. CEL-SCI has relied upon capital generated from the public and private offerings of its common stock and convertible notes. In addition, CEL-SCI has utilized short-term loans to meet its capital requirements. Capital raised by CEL-SCI has been expended primarily to acquire an exclusive worldwide license to use, and later purchase, certain patented and unpatented proprietary technology and know-how relating to the human immunological defense system. Capital has also been used for patent applications, debt repayment, research and development, administrative costs, and the construction of CEL-SCI’s laboratory facilities. CEL-SCI does not anticipate realizing significant revenues until it enters into licensing arrangements regarding its technology and know-how or until it receives regulatory approval to sell its products (which could take a number of years). As a result CEL-SCI has been dependent upon the proceeds from the sale of its securities to meet all of its liquidity and capital requirements and anticipates having to do so in the future. During fiscal year 2013 and 2012, CEL-SCI raised net proceeds of approximately $9,800,000 and $17,000,000, respectively, through the sale of stock and exercise of outstanding warrants. On October 11, 2013, CEL-SCI raised net proceeds of approximately $16,400,000 through the sale of stock and warrants in a public offering.
CEL-SCI will be required to raise additional capital or find additional long-term financing in order to continue with its research efforts. The ability of CEL-SCI to complete the necessary clinical trials and obtain FDA approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately, CEL-SCI must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. CEL-SCI believes that it has enough capital to support its operations for more than the next twelve months.
Es ist immer wieder dasselbe Elend mit diesen Biotech Werten.
Bei Cel-Sci sieht das ziemlich düster aus. Andere Werte springen in Phase II schon mal um 500%.
Seit dem ich Cel-Sci habe kann ich mich nicht an eine Phase von Kurssteigerungen erinnern.
Ich habe den Wert jetzt fast 6 Jahre und so wie es aussieht muss ich noch 3 Jahre warten aber immer noch mit ungewissen Ausgang. Ich weiss nicht was ich davon halten soll?
Bei Cel-Sci sieht das ziemlich düster aus. Andere Werte springen in Phase II schon mal um 500%.
Seit dem ich Cel-Sci habe kann ich mich nicht an eine Phase von Kurssteigerungen erinnern.
Ich habe den Wert jetzt fast 6 Jahre und so wie es aussieht muss ich noch 3 Jahre warten aber immer noch mit ungewissen Ausgang. Ich weiss nicht was ich davon halten soll?
Antwort auf Beitrag Nr.: 46.123.397 von Umckaloabo am 28.12.13 17:30:42Also ich hatte da mal echt Glück/ Zufall...war ja bei 0,33 € damals dabei und raus ich meine so um die 1,35...war ein Megadeal ,mit rund 35000 € Gewinn......( danach immer wieder mal einige % mitgenommen )
das war aber auch mehr Glück als Verstand...seither aber auch schön regelmässig in Biotech verloren .
Jetzt pendelt es sich halt hier auf dem Optionspreis um die 0,65 US$ erst mal ein, ich versuch irgendwo einen Einstiegspunkt zu finden und bin mir immer noch nicht sicher ob es das nun schon war. Nun gut ich denke ich warte einfach mal ab.
Also Rechnen darf man das Teil als Long ja schon gar nicht mehr incl. R/S und Preisverfall.
Altkurs )0,065 US$ da irgendwo- Brutal
das war aber auch mehr Glück als Verstand...seither aber auch schön regelmässig in Biotech verloren .
Jetzt pendelt es sich halt hier auf dem Optionspreis um die 0,65 US$ erst mal ein, ich versuch irgendwo einen Einstiegspunkt zu finden und bin mir immer noch nicht sicher ob es das nun schon war. Nun gut ich denke ich warte einfach mal ab.
Also Rechnen darf man das Teil als Long ja schon gar nicht mehr incl. R/S und Preisverfall.
Altkurs )0,065 US$ da irgendwo- Brutal
CEL-SCI Reports Fiscal 2013 Financial Results and Clinical & Corporate Developments
By Business Wire, January 02, 2014, 10:33:00 AM EDT
VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE MKT:CVM) reported financial results today for the fiscal year ended September 30, 2013. The Company also reported key clinical and corporate developments achieved during, and subsequent to, fiscal 2013.
Corporate Developments Included:
CEL-SCI raised gross proceeds of $21.1 million, subsequent to the end of its 2013 fiscal year, to finance its expanding Phase III trial in the treatment of head and neck cancer.
CEL-SCI's warrants issued in connection with its October 2013 public offering were approved for trading under the ticker symbol "CSCIW", subsequent to the end of its 2013 fiscal year. We expect them to start trading soon, once they have become DTC eligible.
During fiscal 2013, CEL-SCI terminated its former clinical research organization (CRO), inVentiv Health Clinical, LLC (inVentiv), which had been charged with running the Company's Phase III head and neck cancer trial. On October 31, 2013, CEL-SCI filed an arbitration claim against inVentiv under the Commercial Rules of the American Arbitration Association alleging (i) breach of contract, (ii) fraud in the inducement, and (iii) common law fraud, and seeks at least $50 million in damages. On December 12, 2013, inVentiv filed an answer and counterclaim in response to CEL-SCI's claims against it. The counterclaim alleges breach of contract on the part of CEL-SCI and seeks at least $2 million in damages. On December 20, 2013, inVentiv moved to dismiss certain claims. Given that this matter is at a preliminary stage, the Company is not in a position to predict or assess the likely outcome of these proceedings.
CEL-SCI received a key patent in Japan for its investigational Phase III cancer therapy Multikine (Leucocyte Interleukin Inj.).
CEL-SCI signed three co-development agreements with Ergomed, its new co-development partner (and one of the CROs charged with running the Company's Phase III head and neck cancer trial), for a total of up to $16 million. Ergomed will pay for part of CEL-SCI's clinical expenses for three trials including $10 million for the Phase III head and neck cancer trial; $3 million for the treatment for HIV/HPV co-infected men and women with peri-anal warts; and $3 million for the treatment of HIV/HPV co-infected women with cervical dysplasia. Ergomed will be repaid from future sales of Multikine.
Subsequent to the end of fiscal 2013, CEL-SCI signed a Cooperative Research and Development Agreement (CRADA) with the U.S. Navy under which the Navy will conduct a clinical investigation of Multikine in HIV/HPV co-infected men and women with anal warts. The trial will be conducted at San Diego Naval Medical Center and paid for by the US Navy.
Clinical Developments Included:
In 2013, CEL-SCI expanded the reach of its Multikine Phase III trial for the treatment of head and neck cancer into several additional European countries and also increased the number of clinical centers at which the trial is being conducted. In 2014 CEL-SCI plans to expand its Phase III Multikine clinical trial into additional countries and add a significant number of additional clinical investigation sites in order to accelerate patient enrollment.
CEL-SCI announced that a second interim review of the safety data from its open label, randomized, controlled, pivotal Phase III study of Multikine investigational new drug immunotherapy was conducted by the study's Independent Data Monitoring Committee (IDMC). Following their review the IDMC stated that the data raised no safety concerns and recommended that the Phase III study continue unmodified.
CEL-SCI and the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) published data in the Journal of Clinical Investigation, a leading journal for discoveries in basic and clinical biomedical research (2013 J Clin Invest. doi: 10.1172/JCI67550 2013, supplemental information at www.jci.org/articles/view/67550), which demonstrated that CEL-SCI's LEAPS technology halted progression of lethal influenza in three different influenza virus strains, including a drug-resistant strain and a 2009 pandemic flu strain.
The Company presented results at the symposium on "Therapeutic Approaches to Autoimmunity" during the American Association of Immunologists (AAI) 100th annual meeting in Honolulu, HI from an efficacy study in a second animal model of rheumatoid arthritis using its LEAPS technology. The study demonstrated that LEAPS has the potential for use as a therapeutic vaccine to treat different types of rheumatoid arthritis.
Along with its collaborator Northeast Ohio Medical University, CEL-SCI produced a new investigational breast cancer vaccine which was shown to prevent and treat a HER-2/neu expressing breast cancer tumor in a mouse model of the disease. In animals immunized with this vaccine the following was observed : 1) reduction of number of tumors; 2) reduction of tumor mass; 3) absence of tumor in lymph nodes or peritoneal membranes; and 4) changes in angiogenesis.
CEL-SCI reported an operating loss of ($19.87) million in fiscal year 2013 versus an operating loss of ($17.24) million in fiscal year 2012. The rise in operating loss was partially attributable to an increase in research and development expenses to $12.68 million in fiscal year 2013 compared to $10.37 million in fiscal year 2012. CEL-SCI's net loss available to common shareholders for the fiscal year 2013 was ($9.23) million, or ($0.30) per share, versus a loss of ($17.65) million, or ($0.70) per share for the fiscal year 2012. The change in net loss available to common shareholders in fiscal year 2013 was primarily due to the gain on derivative instruments of $10.75 million for fiscal year 2013 versus a gain on derivative instruments of $1.91 million for fiscal year 2012.
Geert Kersten, CEL-SCI's Chief Executive Officer said, "During and immediately following fiscal 2013 we advanced our science on several fronts including adding two new potential treatment indications for Multikine for HIV/HPV co-infected patients. These new indications address critical unmet medical needs, and due to the characteristics of these diseases, the trials may proceed at a more accelerated pace than our ongoing Phase III cancer trial. We also showed important results in animal studies for our LEAPS technology which implied that these products may be possibly useful as treatments for influenza, rheumatoid arthritis and breast cancer."
"Following the termination of our former CRO and the filing of our arbitration claim against them, we are seeing substantial improvement in the pace of our Phase III trial with our two new CROs. We expect to achieve significant progress in our Phase III trial in 2014. Having raised substantial amounts of money during the 4th quarter of 2013, we are able to go full speed towards adding more countries and clinical centers and increasing enrollment for what we believe is the largest Phase III trial in the world for head and neck cancer," Kersten concluded.
Read more: http://www.nasdaq.com/press-release/celsci-reports-fiscal-20…" target="_blank" rel="nofollow ugc noopener">http://www.nasdaq.com/press-release/celsci-reports-fiscal-20…
By Business Wire, January 02, 2014, 10:33:00 AM EDT
VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE MKT:CVM) reported financial results today for the fiscal year ended September 30, 2013. The Company also reported key clinical and corporate developments achieved during, and subsequent to, fiscal 2013.
Corporate Developments Included:
CEL-SCI raised gross proceeds of $21.1 million, subsequent to the end of its 2013 fiscal year, to finance its expanding Phase III trial in the treatment of head and neck cancer.
CEL-SCI's warrants issued in connection with its October 2013 public offering were approved for trading under the ticker symbol "CSCIW", subsequent to the end of its 2013 fiscal year. We expect them to start trading soon, once they have become DTC eligible.
During fiscal 2013, CEL-SCI terminated its former clinical research organization (CRO), inVentiv Health Clinical, LLC (inVentiv), which had been charged with running the Company's Phase III head and neck cancer trial. On October 31, 2013, CEL-SCI filed an arbitration claim against inVentiv under the Commercial Rules of the American Arbitration Association alleging (i) breach of contract, (ii) fraud in the inducement, and (iii) common law fraud, and seeks at least $50 million in damages. On December 12, 2013, inVentiv filed an answer and counterclaim in response to CEL-SCI's claims against it. The counterclaim alleges breach of contract on the part of CEL-SCI and seeks at least $2 million in damages. On December 20, 2013, inVentiv moved to dismiss certain claims. Given that this matter is at a preliminary stage, the Company is not in a position to predict or assess the likely outcome of these proceedings.
CEL-SCI received a key patent in Japan for its investigational Phase III cancer therapy Multikine (Leucocyte Interleukin Inj.).
CEL-SCI signed three co-development agreements with Ergomed, its new co-development partner (and one of the CROs charged with running the Company's Phase III head and neck cancer trial), for a total of up to $16 million. Ergomed will pay for part of CEL-SCI's clinical expenses for three trials including $10 million for the Phase III head and neck cancer trial; $3 million for the treatment for HIV/HPV co-infected men and women with peri-anal warts; and $3 million for the treatment of HIV/HPV co-infected women with cervical dysplasia. Ergomed will be repaid from future sales of Multikine.
Subsequent to the end of fiscal 2013, CEL-SCI signed a Cooperative Research and Development Agreement (CRADA) with the U.S. Navy under which the Navy will conduct a clinical investigation of Multikine in HIV/HPV co-infected men and women with anal warts. The trial will be conducted at San Diego Naval Medical Center and paid for by the US Navy.
Clinical Developments Included:
In 2013, CEL-SCI expanded the reach of its Multikine Phase III trial for the treatment of head and neck cancer into several additional European countries and also increased the number of clinical centers at which the trial is being conducted. In 2014 CEL-SCI plans to expand its Phase III Multikine clinical trial into additional countries and add a significant number of additional clinical investigation sites in order to accelerate patient enrollment.
CEL-SCI announced that a second interim review of the safety data from its open label, randomized, controlled, pivotal Phase III study of Multikine investigational new drug immunotherapy was conducted by the study's Independent Data Monitoring Committee (IDMC). Following their review the IDMC stated that the data raised no safety concerns and recommended that the Phase III study continue unmodified.
CEL-SCI and the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) published data in the Journal of Clinical Investigation, a leading journal for discoveries in basic and clinical biomedical research (2013 J Clin Invest. doi: 10.1172/JCI67550 2013, supplemental information at www.jci.org/articles/view/67550), which demonstrated that CEL-SCI's LEAPS technology halted progression of lethal influenza in three different influenza virus strains, including a drug-resistant strain and a 2009 pandemic flu strain.
The Company presented results at the symposium on "Therapeutic Approaches to Autoimmunity" during the American Association of Immunologists (AAI) 100th annual meeting in Honolulu, HI from an efficacy study in a second animal model of rheumatoid arthritis using its LEAPS technology. The study demonstrated that LEAPS has the potential for use as a therapeutic vaccine to treat different types of rheumatoid arthritis.
Along with its collaborator Northeast Ohio Medical University, CEL-SCI produced a new investigational breast cancer vaccine which was shown to prevent and treat a HER-2/neu expressing breast cancer tumor in a mouse model of the disease. In animals immunized with this vaccine the following was observed : 1) reduction of number of tumors; 2) reduction of tumor mass; 3) absence of tumor in lymph nodes or peritoneal membranes; and 4) changes in angiogenesis.
CEL-SCI reported an operating loss of ($19.87) million in fiscal year 2013 versus an operating loss of ($17.24) million in fiscal year 2012. The rise in operating loss was partially attributable to an increase in research and development expenses to $12.68 million in fiscal year 2013 compared to $10.37 million in fiscal year 2012. CEL-SCI's net loss available to common shareholders for the fiscal year 2013 was ($9.23) million, or ($0.30) per share, versus a loss of ($17.65) million, or ($0.70) per share for the fiscal year 2012. The change in net loss available to common shareholders in fiscal year 2013 was primarily due to the gain on derivative instruments of $10.75 million for fiscal year 2013 versus a gain on derivative instruments of $1.91 million for fiscal year 2012.
Geert Kersten, CEL-SCI's Chief Executive Officer said, "During and immediately following fiscal 2013 we advanced our science on several fronts including adding two new potential treatment indications for Multikine for HIV/HPV co-infected patients. These new indications address critical unmet medical needs, and due to the characteristics of these diseases, the trials may proceed at a more accelerated pace than our ongoing Phase III cancer trial. We also showed important results in animal studies for our LEAPS technology which implied that these products may be possibly useful as treatments for influenza, rheumatoid arthritis and breast cancer."
"Following the termination of our former CRO and the filing of our arbitration claim against them, we are seeing substantial improvement in the pace of our Phase III trial with our two new CROs. We expect to achieve significant progress in our Phase III trial in 2014. Having raised substantial amounts of money during the 4th quarter of 2013, we are able to go full speed towards adding more countries and clinical centers and increasing enrollment for what we believe is the largest Phase III trial in the world for head and neck cancer," Kersten concluded.
Read more: http://www.nasdaq.com/press-release/celsci-reports-fiscal-20…" target="_blank" rel="nofollow ugc noopener">http://www.nasdaq.com/press-release/celsci-reports-fiscal-20…
0,86 gestern After H
Antwort auf Beitrag Nr.: 46.224.899 von Expertchen007 am 14.01.14 15:21:32ne ist ja Pre -M.
News find ich aber keine...deutlich über den 0,65 US$ Optionspreis
News find ich aber keine...deutlich über den 0,65 US$ Optionspreis
wer hat denn diese riesen Stückzahl in Stuttgart geordert, das wären vor dem Split über 500 000 gewesen, da ist doch was im Busch !
http://seekingalpha.com/article/1956461-cel-scis-undervaluat…
Hallo Alfred
@ all,
die letzten Monate waren für uns longs ja schon ziemlich frustrierend. Wobei, Monate ??? => ich meine Jahre
Von meinem Kapital ist noch ca 1/7 übrig. Echt frustrierend.
Die Hoffnung auf Besserung hatte ich schon aufgegeben und alles abgeschrieben.
Aber in den letzten Tagen mehren sich die Anzeichen , dass wir evtl. den Boden gefunden haben und in die andere Richtung drehen.
Bin ja mal gespannt.
Im vorbörslichen Handel in den USA stehen wir übrigens bei 1,04 USD
lg an alle und natürlich auch nach TG
Plaste
Hallo Alfred
@ all,
die letzten Monate waren für uns longs ja schon ziemlich frustrierend. Wobei, Monate ??? => ich meine Jahre
Von meinem Kapital ist noch ca 1/7 übrig. Echt frustrierend.
Die Hoffnung auf Besserung hatte ich schon aufgegeben und alles abgeschrieben.
Aber in den letzten Tagen mehren sich die Anzeichen , dass wir evtl. den Boden gefunden haben und in die andere Richtung drehen.
Bin ja mal gespannt.
Im vorbörslichen Handel in den USA stehen wir übrigens bei 1,04 USD
lg an alle und natürlich auch nach TG
Plaste
.
aber über den Dollar ist sie wieder
.
aber über den Dollar ist sie wieder
.
1 US$ ist auch wichtig...wegen Lisitng
Bin immer noch nicht wieder drin..ich trau dem Teil einfach noch nicht wieder.
Bin immer noch nicht wieder drin..ich trau dem Teil einfach noch nicht wieder.
Sehe ich das richtig das folgende Fonds eingestiegen sind?
Amount beneficially owned:
Sabby Healthcare Volatility Master Fund, Ltd. - 2,482,635
Sabby Volatility Warrant Master Fund, Ltd. - 1,545,288
Sabby Management, LLC - 2,482,635
Hal Mintz - 2,482,635
(b)
Percent of class:
Sabby Healthcare Volatility Master Fund, Ltd. - 4.99%
Sabby Volatility Warrant Master Fund, Ltd. - 3.11%
Sabby Management, LLC - 4.99%
Hal Mintz - 4.99%
http://filings.irdirect.net/data/725363/000153561014000039/c…
Amount beneficially owned:
Sabby Healthcare Volatility Master Fund, Ltd. - 2,482,635
Sabby Volatility Warrant Master Fund, Ltd. - 1,545,288
Sabby Management, LLC - 2,482,635
Hal Mintz - 2,482,635
(b)
Percent of class:
Sabby Healthcare Volatility Master Fund, Ltd. - 4.99%
Sabby Volatility Warrant Master Fund, Ltd. - 3.11%
Sabby Management, LLC - 4.99%
Hal Mintz - 4.99%
http://filings.irdirect.net/data/725363/000153561014000039/c…
Das würde auch die Berg-und Talfahrt des Kurses erklären.
Runterprügeln, kaufen, loslassen ( wie üblich )
Wobei ich eigentlich dachte das der Kurs nur kurz verschnaufen möchte...
Runterprügeln, kaufen, loslassen ( wie üblich )
Wobei ich eigentlich dachte das der Kurs nur kurz verschnaufen möchte...
Antwort auf Beitrag Nr.: 46.333.595 von Plaste am 29.01.14 14:20:44für meinen Teil kann ich nichts mehr dazu sagen,
meine steuerpflichtigen hab ich komplett verkauft mit Verlust , hab da vieles zum gegenrechnen z.b. Thomas Cook oder Heidelberger Druck,
meine steuerfreien bleiben liegen bis zum bitteren Ende,
bin da ziemlich enttäuscht was da abgegangen ist mit dem Split und der Kommunikation von cel,
würde auch nichts mehr nachkaufen, ist mir zu heikel geworden
meine steuerpflichtigen hab ich komplett verkauft mit Verlust , hab da vieles zum gegenrechnen z.b. Thomas Cook oder Heidelberger Druck,
meine steuerfreien bleiben liegen bis zum bitteren Ende,
bin da ziemlich enttäuscht was da abgegangen ist mit dem Split und der Kommunikation von cel,
würde auch nichts mehr nachkaufen, ist mir zu heikel geworden
Hallo,
Tote Hose hier, wa ?!
kurzer Zwischenstand:
23.04.2013 - 117 eingeschriebene Probanten
27.02.2014 - 146 eingeschriebene Probanten, davon ca 84 verabreichte Multikine Dosen
Bis Dezember 2015 sollen alle 800 Probanten eingeschrieben sein.
Ob Sie das schaffen
Ich hoffe mal...
Aber wir wissen ja, die Hoffnung stirbt zuletzt
lg Plaste
Tote Hose hier, wa ?!
kurzer Zwischenstand:
23.04.2013 - 117 eingeschriebene Probanten
27.02.2014 - 146 eingeschriebene Probanten, davon ca 84 verabreichte Multikine Dosen
Bis Dezember 2015 sollen alle 800 Probanten eingeschrieben sein.
Ob Sie das schaffen
Ich hoffe mal...
Aber wir wissen ja, die Hoffnung stirbt zuletzt
lg Plaste
http://finance.yahoo.com/mbview/threadview/?&bn=2791cbf7-a6b…
Interessant.
Steht da am Ende des Berichts das man mit den ersten Ergebnissen schon in 6 Monaten rechnet???
Eine Quelle für den dort rein kopierten, sehr interessanten, Beitrag habe ich leider nicht gefunden.
@ Alfred
Übrigens habe ich letztens mein Depot aufgeräumt und von den letzten Kröten noch ein Paar CVMs gekauft. Irgendwie hatte ich das Gefühl das sowieso alles weg ist. Seit dem steigt Sie wieder. Hoffen wir mal das wir nun die Wende geschafft haben.
Die Hoffung stirbt zuletzt...
lg Plaste
Interessant.
Steht da am Ende des Berichts das man mit den ersten Ergebnissen schon in 6 Monaten rechnet???
Eine Quelle für den dort rein kopierten, sehr interessanten, Beitrag habe ich leider nicht gefunden.
@ Alfred
Übrigens habe ich letztens mein Depot aufgeräumt und von den letzten Kröten noch ein Paar CVMs gekauft. Irgendwie hatte ich das Gefühl das sowieso alles weg ist. Seit dem steigt Sie wieder. Hoffen wir mal das wir nun die Wende geschafft haben.
Die Hoffung stirbt zuletzt...
lg Plaste
Zitat von Plaste: http://finance.yahoo.com/mbview/threadview/?&bn=2791cbf7-a6b…
Interessant.
Steht da am Ende des Berichts das man mit den ersten Ergebnissen schon in 6 Monaten rechnet???
Eine Quelle für den dort rein kopierten, sehr interessanten, Beitrag habe ich leider nicht gefunden.
@ Alfred
Übrigens habe ich letztens mein Depot aufgeräumt und von den letzten Kröten noch ein Paar CVMs gekauft. Irgendwie hatte ich das Gefühl das sowieso alles weg ist. Seit dem steigt Sie wieder. Hoffen wir mal das wir nun die Wende geschafft haben.
Die Hoffung stirbt zuletzt...
lg Plaste
Preliminary results could be available in about six months, but FDA approval on the new drug would likely take a few years
http://www.kinston.com/news/local/kinston-doctor-heading-up-…
Danke.
@ all:
http://seekingalpha.com/article/2087783-cel-scis-multikine-p…
Wenn jetzt noch im Bereich Biotech eine Art Branchenrotation einsetzt und alles auf den Bereich von Aktien, die bei der Krebsbekämpfung das Imunsystem Boosten, dreht, haben wir gewonnen.
Hier noch ein Übersetzungsversuch:
http://www.online-translator.com/siteTranslation/autolink/?s…
Aber Ihr wisst ja alle,
Die Hoffnung stirbt zuletzt.
LG Plaste
@ all:
http://seekingalpha.com/article/2087783-cel-scis-multikine-p…
Wenn jetzt noch im Bereich Biotech eine Art Branchenrotation einsetzt und alles auf den Bereich von Aktien, die bei der Krebsbekämpfung das Imunsystem Boosten, dreht, haben wir gewonnen.
Hier noch ein Übersetzungsversuch:
http://www.online-translator.com/siteTranslation/autolink/?s…
Aber Ihr wisst ja alle,
Die Hoffnung stirbt zuletzt.
LG Plaste
Nachtrag:
Wenn man den Bericht etwas durchrechnet:
MK 70 Mio = Kurs von 1,27 € ( aktuell )
MK 700 Mio = Kurs von 12,70 €
MK 12 Mrd = Kurs von 200,00 € und mehr
Ich bin für die dritte Möglichkeit.
Übrigens scheint der Beitrag für Wirbel zu sorgen. Schaut Euch mal die nachbörslichen Kurse an.
Wenn man den Bericht etwas durchrechnet:
MK 70 Mio = Kurs von 1,27 € ( aktuell )
MK 700 Mio = Kurs von 12,70 €
MK 12 Mrd = Kurs von 200,00 € und mehr
Ich bin für die dritte Möglichkeit.
Übrigens scheint der Beitrag für Wirbel zu sorgen. Schaut Euch mal die nachbörslichen Kurse an.
Antwort auf Beitrag Nr.: 46.629.027 von Plaste am 14.03.14 10:07:57dein wort in gottes ohr, allerdings haben wir noch nicht mal den alten kurs wieder ( vor dem resplit )
kurs splittbereinigt 0,15 cent.....
Antwort auf Beitrag Nr.: 46.635.137 von vfbler74 am 15.03.14 09:36:49klar. Schau Dir einfach mal den Verlauf von Dendreon an....
Aber Du weißt ja,
Die Hoffnung ...
LG Plaste
Aber Du weißt ja,
Die Hoffnung ...
LG Plaste
ich hätte 2 mal zu 2 Dollar mal verkaufen können.....hofft aber auf 5 oder 10 Dollar.....war auch lange an Board...
Hmmm...noch ist es relativ günstig vor R/S gerechnet...ich denk ich werd mal wieder anfangen was aufzubauen.
Hallo zusammen,
kennt Ihr das schon?
http://www.youtube.com/watch?v=TYtOBXrFKBE
PS: bei 5,60 USD bin ich ungefähr bei +/- 0
=> soll heißen, ich bin jetzt mal Überoptimist
kennt Ihr das schon?
http://www.youtube.com/watch?v=TYtOBXrFKBE
PS: bei 5,60 USD bin ich ungefähr bei +/- 0
=> soll heißen, ich bin jetzt mal Überoptimist
Artikel auf Thestreet.com
http://www.thestreet.com/story/12537984/1/insider-buying-is-…
http://www.thestreet.com/story/12537984/2/insider-buying-is-…
Seite 2 bzw. der zweite Link dort steht u.a.:
2.CEL-SCI Corp. (CVM):Engages in the research and development of drugs and vaccines. Market cap at $73.77M, most recent closing price at $1.53.
Over the last six months, insiders were net buyers of 556,825 shares, which represents about 1.11% of the company's 50.39M share float.
SMA 50: 41.08%.
lg Plaste
http://www.thestreet.com/story/12537984/1/insider-buying-is-…
http://www.thestreet.com/story/12537984/2/insider-buying-is-…
Seite 2 bzw. der zweite Link dort steht u.a.:
2.CEL-SCI Corp. (CVM):Engages in the research and development of drugs and vaccines. Market cap at $73.77M, most recent closing price at $1.53.
Over the last six months, insiders were net buyers of 556,825 shares, which represents about 1.11% of the company's 50.39M share float.
SMA 50: 41.08%.
lg Plaste
CEL-SCI CEO Geert Kersten to Be Interviewed Live Today on Clear Channel Business Talk Radio
Interview Scheduled at 11:05am PDT / 12:05 pm MDT / 2:05pm EDT on the Traders Network Radio Show, Hosted by Michael Yorba
http://finance.yahoo.com/news/cel-sci-ceo-geert-kersten-1426…
wäre schön wenn jemand eine deutsche Zusammenfassung hin bekommen würde.
mfg Plaste
Interview Scheduled at 11:05am PDT / 12:05 pm MDT / 2:05pm EDT on the Traders Network Radio Show, Hosted by Michael Yorba
http://finance.yahoo.com/news/cel-sci-ceo-geert-kersten-1426…
wäre schön wenn jemand eine deutsche Zusammenfassung hin bekommen würde.
mfg Plaste
Antwort auf Beitrag Nr.: 46.698.835 von Plaste am 25.03.14 16:22:29Ja, mein Schulenglisch ist auch grottenschlecht nach 40 Jahren, aber am Kurs wird man es auch sehen glaube ich.
Die News der letzten Tage solltet Ihr ja mitbekommen haben.
Die Insiderkäufe gestern oder vorgestern auch.
Folgenden Artikel find ich ganz net:
http://seekingalpha.com/article/2122483-cel-sci-sees-rapid-e…
Übrigens wenn man den Text in den Googleübersetzer kopiert versteht man auch das meiste :-)
lg Plaste
PS: wird Zeit das wir die 2,00 USD knacken...
Die Insiderkäufe gestern oder vorgestern auch.
Folgenden Artikel find ich ganz net:
http://seekingalpha.com/article/2122483-cel-sci-sees-rapid-e…
Übrigens wenn man den Text in den Googleübersetzer kopiert versteht man auch das meiste :-)
lg Plaste
PS: wird Zeit das wir die 2,00 USD knacken...
Geert hat mal wieder 170.000 Stk. Optionen gekauft.
Sag mal, kann man die Optionen auch irgendwo kaufen? Hat jemand ne ISIN oder sowas?
Sag mal, kann man die Optionen auch irgendwo kaufen? Hat jemand ne ISIN oder sowas?
Antwort auf Beitrag Nr.: 46.795.977 von Plaste am 09.04.14 20:42:40schau mal in den News, da müßte was zu finden sein - after hours sieht böse aus !!!!
Hallo,
was bedeutet Eurer Meinung nach dieses Angebot?
Warum ist after hours so mies?
Gruß
frankas
was bedeutet Eurer Meinung nach dieses Angebot?
Warum ist after hours so mies?
Gruß
frankas
Antwort auf Beitrag Nr.: 46.815.715 von frankashh am 13.04.14 12:11:10Führt wieder zu Verwässerng und mehr Aktien denk ich mal
Da bleibt ja nur die Frage ob CEL SCI es schaft eine Zulassung zu bekommen. Die Fabrik steht ja, aber mir ist nicht klar ob die Kapazität für die Klinik Chargen alleinig ist oder ob Sie gebaut worden ist für den potentiellen Launch.
Gruß
Gruß
Antwort auf Beitrag Nr.: 46.815.715 von frankashh am 13.04.14 12:11:10http://www.nasdaq.com/symbol/cvm/after-hours
böser Verlauf mal wieder in USA.....also "sollte " es an die 0,90 - 0,85 US$ mal wieder ranlaufen bin ich wieder dabei, vorher mir etwas zu risikoreich, aber ob das klappt ist fraglich .
http://www.streetinsider.com/Corporate+News/CEL-SCI+Corp.+%2…
CEL-SCI Corporation (AMEX: CVM) announced that it has priced a “best efforts” underwritten public offering of units of common stock and warrants at a price of $1.40 per unit for gross proceeds of approximately $10 million, prior to deducting underwriting commissions and offering expenses of the Company. Each unit consists of one share of common stock and 0.25 warrant to purchase one share of common stock. The common stock and warrants will separate immediately. The warrants are immediately exercisable, expire October 17, 2014 and have an exercise price of $1.58. The offering is expected to close on or about April 17, 2014, subject to the satisfaction of customary closing conditions.
CEL-SCI Corporation (AMEX: CVM) announced that it has priced a “best efforts” underwritten public offering of units of common stock and warrants at a price of $1.40 per unit for gross proceeds of approximately $10 million, prior to deducting underwriting commissions and offering expenses of the Company. Each unit consists of one share of common stock and 0.25 warrant to purchase one share of common stock. The common stock and warrants will separate immediately. The warrants are immediately exercisable, expire October 17, 2014 and have an exercise price of $1.58. The offering is expected to close on or about April 17, 2014, subject to the satisfaction of customary closing conditions.
Proxy Statement
Payment of Filing Fee
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS
TO BE HELD July 22, 2014
To the Shareholders:
Notice is hereby given that the annual meeting of the shareholders of CEL-SCI Corporation ("CEL-SCI") will be held at 4820-C Seton Drive, Baltimore, MD 21215, on July 22, 2014 at 10:30 a.m. local time, for the following purposes:
(1) to elect the directors who shall constitute CEL-SCI's Board of Directors for the ensuing year;
(2) to approve the adoption of CEL-SCI's 2014 Incentive Stock Bonus Plan which will allow awards of CEL-SCI's common stock to employees for meeting major CEL-SCI milestones spelled out in advance (performance based).
(3) to approve on an advisory basis, compensation of CEL-SCI's executive officers;
(4) to approve on an advisory basis, the frequency of advisory votes on the compensation of CEL-SCI's executive officers and
(5) to ratify the appointment of BDO USA, LLP as CEL-SCI's independent registered public accounting firm for the fiscal year ending September 30, 2014;
to transact such other business as may properly come before the meeting.
June 9, 2014 Geert R. Kersten, Chief Executive Officer
The Board of Directors solicits the enclosed proxy. Your vote is important no matter how large or small your holdings. To assure your representation at the meeting, please vote promptly.
Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting to be held on July 22, 2014. This Proxy Statement and our Form 10-K are available at:
www.irdirect.net/cvm/sec_filings/
http://de.advfn.com/p.php?pid=nmona&article=62399837
Payment of Filing Fee
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS
TO BE HELD July 22, 2014
To the Shareholders:
Notice is hereby given that the annual meeting of the shareholders of CEL-SCI Corporation ("CEL-SCI") will be held at 4820-C Seton Drive, Baltimore, MD 21215, on July 22, 2014 at 10:30 a.m. local time, for the following purposes:
(1) to elect the directors who shall constitute CEL-SCI's Board of Directors for the ensuing year;
(2) to approve the adoption of CEL-SCI's 2014 Incentive Stock Bonus Plan which will allow awards of CEL-SCI's common stock to employees for meeting major CEL-SCI milestones spelled out in advance (performance based).
(3) to approve on an advisory basis, compensation of CEL-SCI's executive officers;
(4) to approve on an advisory basis, the frequency of advisory votes on the compensation of CEL-SCI's executive officers and
(5) to ratify the appointment of BDO USA, LLP as CEL-SCI's independent registered public accounting firm for the fiscal year ending September 30, 2014;
to transact such other business as may properly come before the meeting.
June 9, 2014 Geert R. Kersten, Chief Executive Officer
The Board of Directors solicits the enclosed proxy. Your vote is important no matter how large or small your holdings. To assure your representation at the meeting, please vote promptly.
Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting to be held on July 22, 2014. This Proxy Statement and our Form 10-K are available at:
www.irdirect.net/cvm/sec_filings/
http://de.advfn.com/p.php?pid=nmona&article=62399837
Antwort auf Beitrag Nr.: 47.078.454 von binda am 31.05.14 03:05:29
hier war es nun lang genug ruhig.
Ende diesen Jahres sollen ja nun die Einschreibungen von PIII Multikine beendet sein.
Am 31.01.15 hatten wir 352 gemeldete Probanden.
Nur mal so nebenbei, am 27.02.2014 waren 146 Probanden gemeldet.
Natürlich sieht das nach den o.a. Zahlen nicht unbedingt so aus, als ob wir bis Ende des Jahres die 800 Probanden zusammenbekommen. Aber man sollte sich die Dynamik der letzten Monate bei den Einschreibungen und der Entstehung der neuen Zentren anschauen.
Ich denke die Chancen stehen 50:50
Übrigens, nachdem ich ja nun bei -90% stehe sollte ich nicht all zu optimistisch sein. Aber von einem bin ich überzeugt:
Innerhalb der nächsten 12 - 18 Monate werden wir wissen ob wir mit unserer Anlageentscheidung richtig liegen.
Wobei nach meiner Meinung noch folgende Risiken bestehen:
CVM ist ein einziger Betrug ( was man im US Board immer wieder versucht den Anlegern zu erklären)
CVM geht das Geld aus
die PII Ergebnisse bestätigen sich nicht => Multikine funktioniert nicht
und nach meiner Meinung ist das größte Risiko:
Das, sollten sich die PII Ergebnisse bestätigen, ein großer Pharma oder Biotechkonzern versucht die Marktreife von Multikine endgültig zu verhindern, um sein Produkte weiterhin zu vertreiben.
Schließlich ist Multikine, sollte es wirken, nicht nur ein riesiger Blockbuster. Es ist ein Krebsmedikament, welches bei vielen verschiedenen Arten von Krebs eingesetzt werden kann....
Meinungen zu den 4 Risiken?
@ an die alten Hasen.
Ich hoffe alles gesund
Seid Ihr alle da ....
Hallo Zusammen, hier war es nun lang genug ruhig.
Ende diesen Jahres sollen ja nun die Einschreibungen von PIII Multikine beendet sein.
Am 31.01.15 hatten wir 352 gemeldete Probanden.
Nur mal so nebenbei, am 27.02.2014 waren 146 Probanden gemeldet.
Natürlich sieht das nach den o.a. Zahlen nicht unbedingt so aus, als ob wir bis Ende des Jahres die 800 Probanden zusammenbekommen. Aber man sollte sich die Dynamik der letzten Monate bei den Einschreibungen und der Entstehung der neuen Zentren anschauen.
Ich denke die Chancen stehen 50:50
Übrigens, nachdem ich ja nun bei -90% stehe sollte ich nicht all zu optimistisch sein. Aber von einem bin ich überzeugt:
Innerhalb der nächsten 12 - 18 Monate werden wir wissen ob wir mit unserer Anlageentscheidung richtig liegen.
Wobei nach meiner Meinung noch folgende Risiken bestehen:
CVM ist ein einziger Betrug ( was man im US Board immer wieder versucht den Anlegern zu erklären)
CVM geht das Geld aus
die PII Ergebnisse bestätigen sich nicht => Multikine funktioniert nicht
und nach meiner Meinung ist das größte Risiko:
Das, sollten sich die PII Ergebnisse bestätigen, ein großer Pharma oder Biotechkonzern versucht die Marktreife von Multikine endgültig zu verhindern, um sein Produkte weiterhin zu vertreiben.
Schließlich ist Multikine, sollte es wirken, nicht nur ein riesiger Blockbuster. Es ist ein Krebsmedikament, welches bei vielen verschiedenen Arten von Krebs eingesetzt werden kann....
Meinungen zu den 4 Risiken?
@ an die alten Hasen.
Ich hoffe alles gesund
Antwort auf Beitrag Nr.: 49.015.415 von Plaste am 08.02.15 22:56:52http://www.wallstreet-online.de/diskussion/1207442-1-10/cel-…
ich hab einen neuen Thread eröffnet.
Wäre schön wenn wir uns alle dort treffen.
LG Plaste
http://www.wallstreet-online.de/diskussion/1207442-1-10/cel-…
ich hab einen neuen Thread eröffnet.
Wäre schön wenn wir uns alle dort treffen.
LG Plaste
http://www.wallstreet-online.de/diskussion/1207442-1-10/cel-…
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
98 | ||
65 | ||
65 | ||
55 | ||
52 | ||
28 | ||
28 | ||
24 | ||
22 | ||
22 |
Wertpapier | Beiträge | |
---|---|---|
22 | ||
22 | ||
22 | ||
18 | ||
18 | ||
17 | ||
16 | ||
16 | ||
16 | ||
15 |